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Genetic muscle disorders such as facioscapulohumeral muscular dystrophy 
(FSHD) deprive patients of their physical strength and quality of life. Animal models 
have been indispensable in the research investigation and therapeutic development for 
genetic muscle disorders. But the successful leap from bench to bedside rarely happens 
because the animal model is not human and cannot predict human response to therapy 
precisely. Herein, we try to create a ‘living and breathing’ human muscle inside a mouse 
host and demonstrate the feasibility and validity of human to mouse xenografts as a 
preclinical model of myopathy. Human skeletal muscle biopsies as well as autopsies 
transplanted into the anterior tibial compartment of the hindlimbs of NOD-Rag1null 
IL2rγnull (NRG) immunodeficient host mice regenerate new vascularized and innervated 
myofibers from human myogenic precursor cells. The grafts exhibit contractile and 
calcium release behavior, characteristic of functional muscle tissue.  
The validity of the human graft as a model of FSHD is demonstrated in disease 
biomarker studies, showing that gene expression profiles of xenografts mirror those of 
the donor muscles. These findings illustrate the value of a new experimental model of 
muscle disease as a feasible and valid preclinical tool to better investigate the 
pathogenesis of human genetic myopathies and to more accurately predict their response 
to novel therapeutics.  
We also report a proof-of-concept study using antisense phosphorodiamidate 
morpholino oligonucleotides (PMOs) to suppress DUX4 expression, which is believed to 
be the causative genetic defect of FSHD currently, in FSHD myotubes and xenografts 
derived from patients. The most effective PMO FM10 had no significant cell toxicity. 
 iii 
RNA-seq analyses of FSHD and control myotubes revealed that FM10 down-regulated 
many transcriptional targets of DUX4, without overt off-target effects. Treatment with 
FM10 in FSHD patient muscle xenografts also down-regulated DUX4 and DUX4 targets. 
These findings demonstrate the potential of antisense PMOs as an FSHD therapeutic 
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 In Chapter 1, I will provide an introduction to the disease facioscapulohumeral 
muscular dystrophy (FSHD), the challenges faced in creating animal models for FSHD, 
and the use of xenograft models in therapeutic development. In Chapter 2, I will present 
the establishment of the human skeletal muscle xenograft model, specifically for FSHD. 
In Chapter 3, I will present a proof-of-concept study of using antisense 
phosphorodiamidate morpholino oligonucleotides (PMOs) as a potential FSHD 





Skeletal muscle tissues, composing a third of the body mass in a healthy 
individual (1), are essential for support, protection and movement of the body. There are 
many disorders of skeletal muscle, and most individuals will suffer from a skeletal 
muscle disorder at some point in their lives. These include genetic disorders of muscle, 
acquired primary myopathies (including toxic, metabolic, and inflammatory myopathies), 
acquired myopathy secondary to a chronic illness (including infections, cancer, and 
congestive heart failure), or sarcopenia, the age related loss of muscle. Our lab is devoted 
to developing novel therapies for muscle disorders in order to improve function and 
quality of life.   
Animal models are essential in the investigation of disease pathogenesis and 
therapeutic development. The significance of the project detailed here is that a human 
muscle xenograft model independent of specific molecular hypothesis may translate well 
to human clinical trials and could be made rapidly available for diseases which do not 
currently have an accepted animal model. Such an in vivo model would facilitate entry of 
novel therapeutics to clinical trials in underserved disease population, and in the present 
study this is demonstrated specifically with facioscapulohumeral dystrophy (FSHD).  
 
Facioscapulohumeral dystrophy   
Facioscapulohumeral dystrophy (FSHD) was first described in 1885 by the 
French neurologists Landouzy and Dejerine (2) It is characterized by asymmetric muscle 
weakness and wasting (atrophy) of specific muscle groups indicated by the name: those 
of the face (facio-), around the shoulder blades (scapulo-), and in the upper arms 
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(humeral) (Figure 1.1). FSHD is one of the most prevalent neuromuscular disorders, 
affecting 1-9 : 100,000 individuals worldwide (3). 
FSHD is classically considered an autosomal dominant muscle disorder; however, 
up to 30% of cases are sporadic, caused by de novo mutations (4). Traditionally, 
physicians believe the progression of disease starts with asymmetric weakness of muscles 
in the face and shoulder‑girdle, later involving pelvic and proximal lower limb muscles. 
Recent whole body MRI studies have revealed that while FSHD can go on to affect most 
any skeletal muscle, the most frequently and severely involved muscle overall is the 
semimembranosus. Paraspinal muscles and muscles of the abdominal wall are also 
among the most frequently involved(5). In rare cases, there are extramuscular 
manifestations including a retinal exudative retinopathy (Coats disease) and hearing loss 
(6). Disease onset appears from infancy to late life but typically in the second decade for 
men and by the third decade of life for women. The clinical spectrum is widely variable, 
ranging from asymptomatic gene carriers to wheelchair bound patients, which matches 
the great variety in severity of muscle pathology (Figure 1.2). Interestingly, FSHD affects 
males more severely and more frequently than females, although the cause is not yet clear 
(7). FSHD has no particular racial, geographic or ethnic distribution, and studies 
worldwide show similar prevalence across races (8-10). Currently genetic testing is the 
only way to confirm a FSHD diagnosis, while no biochemical, histological, or 





Figure 1.1 Clinical features of FSHD (11). 
 
Figure 1.2 Example images of H&E stained muscle sections from healthy, mildly 
affected, and severely affected FSHD donors.  
 
FSHD pathogenesis has been one of the most puzzling enigmas in human genetics 
for the past two decades. There was always a consensus that the disease was caused by a 
gain-of-function mutation that activate the transcription of a region that is normally 
repressed post development. There are two subtypes of FSHD based on the genetics and 
epigenetics as shown in Figure 1.3 summarized by Himeda et al.:  FSHD1, the classical 
form accounting for 95% of FSHD cases, is associated with pathogenic contraction of 
D4Z4 macrosatellite repeats on a 4qA subtype of chromosome 4; and FSHD2 is 
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contraction-independent but associated with mutations in the chromatin regulator gene 
SMCHD1 (structural maintenance of chromosomes hinge-domain protein 1). In healthy 
individuals, the D4Z4 macrosatellite repeat array in the subtelomere of chromosome 4 at 
4q35 varies between 11 and 100 repeat units and is marked by hypermethylation and 
compact chromatin structure, indicating the state of transcriptional repression.  In 
FSHD1, the repeat units are contracted to 1-10 units and are associated with local 
hypomethylation and chromatin relaxation on chromosome 4. With the disease-
permissive 4qA allele, the toxic DUX4-fl (double homeobox protein 4-full length) 
expression is no longer silenced in skeletal muscle. Recent studies have shown an 
imperfect correlation between the size of the repeat units and disease severity, as FSHD1 
patients with 1-3 repeat units tend to be more clinically severe with younger onset ages 
while patients with 8-10 repeat units usually present milder symptoms or may be 
asymptomatic even in late adulthood. In FSHD2, mutations in SMCHD1 cause 
hypomethylation of chromosomes 4 and 10, allowing chromosome 4 to express the toxic 
DUX4 transcript in the case of the permissive 4qA allele. It is recently suggested that 
SMCHD1 may act as a genetic modifier of FSHD1 because SMCHD1 gene mutations are 
identified in individuals with more severe phenotype and SMCHD1 protein directly binds 
to D4Z4 and suppresses somatic expression of D4Z4 (12, 13). The high variability of 
disease severity between FSHD individuals, even within the same family with the same 
contracted D4Z4 allele and permissive haplotype, suggests that there are likely other 




Figure 1.3 FSHD is a genetic and epigenetic disorder (14) 
 
While there is consensus on the genetic cause of the disease, the pathogenesis of 
FSHD is still under investigation. Several candidate genes located within or close to the 
D4Z4 locus, including FRG1 (FSHD region gene 1) (15, 16), FRG2 (FSHD region gene 
2) (17), ANT1 (adenine nucleotide translocase 1) (18), FAT1 (FAT Atypical Cadherin 1) 
(19), and DUX4c (20), have been proposed as FSHD pathogenesis mediators based on 
differential expression between FSHD and healthy myoblasts, but little consensus is 
reached in subsequent validation using large cohort studies. However one gene that has 
been consistently shown to be misexpressed in FSHD myoblasts and patient biopsies is 
DUX4, a retrogene exclusive to Old World Primates. Although located within each D4Z4 
repeat unit, DUX4 is only transcribed from the last D4Z4 unit and its mRNA needs to be 
stabilized by splicing to a polyadenylation signal present only in a 4qA disease-
permissive allele. DUX4 encodes two different protein isoforms generated through 
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alternative mRNA splicing: a non-pathogenic short form, DUX4-s, that is often expressed 
in healthy somatic cells and a toxic full-length form DUX4-fl, which is expressed in 
muscle and other tissues during development and post development in testis, but silenced 
in healthy somatic cells (Figure 1.4). However even in FSHD myoblasts in vitro DUX4-fl 
is expressed at very low levels, around 1:1000 nuclei. DUX4-fl expression is shown to be 
cytotoxic in myoblasts and disrupts myotube formation in vitro. The current hypothesis is 
that DUX4-fl expression activates a network of DUX4 targets, including germline genes 
and immune modulators, and eventually causes muscle pathology. Nevertheless, recent 
large family cohort studies where many asymptomatic patients with detectable DUX4 
expression were identified indicate other disease modulators may be important in FSHD 
manifestation.    
 
Figure 1.4. Alternate DUX4 transcript splicing creates multiple isoforms. 
 
Models for FSHD 
Researchers have built various cell models to advance understanding of this 
complex disease. Experiments over-expressing DUX4-fl in various cell types with 
plasmid or viral constructs showed DUX4 is a transcription factor that can turn on a panel 
of downstream targets. Transfection studies expressing DUX4 in cell lines showed 
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that DUX4 transcripts and protein localize to the nucleus and are directly toxic to cells 
leading to apoptosis. DUX4 expression can also inhibit myogenesis (21-24).  
In primary myoblasts derived from FSHD patient muscle, it is found that DUX4 
was expressed at low levels, being found in approximately 1 out of every 1,000 nuclei, 
and has a curious pattern of being expressed in a gradient in aligned nuclei as shown in 
Figure 1.5 (25). In addition, the nuclei that showed abundant expression of DUX4 also 
showed changes consistent with DUX4-mediated toxicity, including nuclear aggregation 
of DUX4 protein and apoptosis (26). Transcriptomic analyses in human and mouse cells 
in response to ectopic DUX4 expression demonstrated that DUX4 regulates human and 
mouse transcriptomes differentially; specifically inflammation, BMP signaling and NRF-
2 mediated oxidative stress are the top three affected pathways in human muscle cells 
while p53 signaling, cell cycle regulation and cellular energy metabolism are the top hits 
in mouse C2C12 cells (27).  
 
Figure 1.5 DUX4 immunostaining in primary myotube culture derived from 




Animal models are essential to study potential disease mechanisms, to identify 
therapeutic targets, and eventually to test potential therapeutic strategies. However, the 
complexity of the disorder and the underlying uncertainty about the pathogenesis make 
FSHD a challenging disorder for the creation of animal models. Even the near-consensus 
causal gene DUX4 is only found in Old World primates and not in any common 
laboratory animal species (28), which eliminates the possibility of having a ‘natural’ 
model of disease like the mdx mouse and GRMD dog models for DMD (Duchenne 
muscular dystrophy) (29). Additionally, the extremely low level of DUX4 expression in 
FSHD patient cells and biopsies highlights yet another challenge to create a model where 
DUX4 expression is near the physiological level found in patients. Furthermore, 
emerging evidence indicates other modifier genes may be essential for disease 
manifestation as studies identify DUX4 expression in non-manifesting patients.   
Zebrafish are considered an ideal model organism to study the vertebrate muscle 
development because of the ease of visualization of muscle abnormalities (30). 
Mitsuhashi et al. created a DUX4 zebrafish model by directly injecting DUX4-fl mRNA 
at the one-cell stage of embryogenesis, which resulted in embryonic lethality at high 
dosage. Nevertheless, at low levels DUX4 mRNA induced disorganization of muscle 
structure, asymmetric abnormality of the eyes and fins, and disrupted swimming patterns, 
indicating the zebrafish model may be helpful in high-throughput screening of potential 
therapeutics in current medical chemistry libraries by assaying birefringence and swim 
pattern (31).  
Researchers have been working on creating a mouse model for FSHD, but the fact 
that DUX4 and a number of DUX4-fl gene targets are primate specific presents a big 
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challenge. The first mouse model was created by Wallace et al. by intra-muscular 
injection of DUX4-overexpressing adeno-associated virus type 6 (AAV6). As DUX4 
expression is detected one week post-injection, significant muscle damage was presented 
by degenerating myofibers and infiltrating mononuclear cells and positive staining of 
apoptosis markers, indicating DUX4 toxicity in vivo. They also demonstrated this 
myopathic effect is p53 dependent (32). Recently, researchers attempted to insert the 
DUX4-containing human D4Z4 locus to the mouse genome to create a transgenic mouse 
model. Krom et al. integrated an FSHD contraction including 2.5 D4Z4 repeats on a 
permissive haplotype background (termed D4Z4-2.5 mouse), while also generating a 
control mouse with 12.5 D4Z4 repeats representing the normal size in healthy humans 
(33).  Even though DUX4 transcript expression is detected in multiple muscle groups in 
the D4Z4-2.5 mice, no muscle weakness or wasting was observed, nor were 
abnormalities in morphology or histology. The only phenotype is keratitis detected at 8-
12 weeks. Despite the recapitulation of the FSHD hypomethylation epigenetics and 
sporadic DUX4 expressing genetics, the lack of relevant pathology indicates other 
players in FSHD pathogenesis.  
Overall there is not an accepted animal model of FSHD, which has had a direct 
negative impact on therapeutic development for FSHD: there have been very few clinical 
trials. For other neuromuscular diseases, such as Amyotrophic Lateral Sclerosis (ALS) 
and DMD which have mouse models (SOD1G93A and mdx) there are dozens of ongoing 






Xenograft model   
Primary xenograft models have become widespread in the study of various 
cancers and development of novel chemotherapeutics (34-36). In these models, patient 
tumor cells are typically dissociated and injected into the subcutaneous space or the flank 
of mice to determine if the human tumor will respond to a specific therapeutic regime.  
Such human tumor xenografts have led to the successful development of effective 
treatments for common cancers including multiple myeloma, as well as personalized 
therapeutic approaches for individual patients. For example, the efficacy of Velcade and 
Melphalan was first demonstrated in xenografts and are now used as standard of care in 
multiple myeloma (37, 38).  
Human muscle xenografts have previously been attempted only from dissociated 
cells.  Several laboratories have injured and/or irradiated the legs of mice and injected 
human muscle progenitor cells. The engraftment of human muscle cells in these studies is 
not high, and tends to be largely perifascicular (39, 40). In addition, this technique also 
leads to a high rate of human-mouse hybrid myofibers because it is highly difficult to 
eliminate all mouse myoblasts from the graft area.   
The abundance of stem cells in skeletal muscle makes a tissue based xenograft 
possible. Satellite cells, which account for ~2–6% of the nuclei in adult skeletal muscle, 
are the main source of stem cells for repair of postnatal skeletal muscle through 
regenerative myogenesis, induced by muscle wear-and-tear, injury, or disease-related 
atrophy (41). During regeneration, satellite cells are induced to proliferate and form 
myoblasts while also maintaining a pool of quiescent stem cells. The activated myoblasts 
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then differentiate and fuse with the damaged myofiber or with other myoblasts to form 
multinucleated myotubes, regenerating functional muscle. 
Researchers have experimented with free muscle grafts in multiple animal models 
in the past, where a piece of muscle is excised from its original site by both tendons and 
transplanted into another site within the same animal. Collins et al. isolated single 
myofibers with their associated satellite cells and transplanted into the muscles of   
radiation-ablated muscles of an mdx host (42). They showed the great myogenic potential 
of satellite cells in a single fiber in that one myofiber can produce sufficient 
differentiation-competent progeny to generate thousands of myonuclei (Figure 1.6).   
 





A tissue-based xenograft model for human muscle disorders, depicted in Figure 
1.7, has many advantages. Specifically for FSHD, these include that the graft features the 
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complex genetic and epigenetic abnormality that exists in the human disease which may 
never be reproducible in a genetically engineered mouse model. Additionally, the actual 
human tissue response to drugs that can be studied in these mice will more likely 
translate to patients. There are also disadvantages, including labor intensive nature of 
creating individual mice, limitations from the availability of FSHD muscle and the 
inability to study whole animal function. In the next two chapters, I will demonstrate the 
both feasibility and functionality of such a model. 
   
 
Figure 1.7. Summary of the xenograft concept for modeling human skeletal 
















Chapter 2. Human skeletal muscle xenograft as a new preclinical 

















Yuanfan Zhang, Oliver D. King, Fedik Rahimov, Takako I. Jones, Christopher W. 
Ward, Jaclyn P. Kerr, Naili Liu, Charles P. Emerson, Jr, Louis M. Kunkel, Terence A. 
Partridge, and Kathryn R. Wagner. Human skeletal muscle xenograft as a new preclinical 
model for muscle disorders. Hum. Mol. Genet. (2014) 23 (12): 3180-3188. 




Development of novel therapeutics requires good animal models of disease. 
Disorders for which good animal models do not exist have very few drugs in 
development or clinical trial. Even where there are accepted, albeit imperfect models, the 
leap from promising preclinical drug results to positive clinical trials commonly fails, 
including in disorders of skeletal muscle. The main alternative model for early drug 
development, tissue culture, lacks both the architecture and, usually, the metabolic 
fidelity of the normal tissue in vivo. Herein, we demonstrate the feasibility and validity of 
human to mouse xenografts as a preclinical model of myopathy. Human skeletal muscle 
biopsies transplanted into the anterior tibial compartment of the hindlimbs of NOD-
Rag1null IL2rγnull immunodeficient host mice regenerate new vascularized and 
innervated myofibers from human myogenic precursor cells. The grafts exhibit 
contractile and calcium release behavior, characteristic of functional muscle tissue. The 
validity of the human graft as a model of facioscapulohumeral muscular dystrophy is 
demonstrated in disease biomarker studies, showing that gene expression profiles of 
xenografts mirror those of the fresh donor biopsies. These findings illustrate the value of 
a new experimental model of muscle disease, the human muscle xenograft in mice, as a 
feasible and valid preclinical tool to better investigate the pathogenesis of human genetic 
myopathies and to more accurately predict their response to novel therapeutics. 





 Animal models of myopathy are an important feature of the development of novel 
therapies for humans. Of these, the mouse is certainly the most convenient and popular 
mammalian model.  However, mouse models for many human diseases such as Duchenne 
muscular dystrophy (DMD) are frequently criticized for their limitations,  especially the 
lack of translation from positive preclinical studies to positive clinical trial (43, 44).  As a 
notable example, the only drugs proven in randomized, placebo-controlled, clinical trials 
to benefit boys with DMD are glucocorticosteroids, which do not improve the condition 
of the murine mdx model in long term studies (45-47).   Despite this, preclinical efficacy 
testing in animal models remains a near obligatory requirement in industry and academia 
for neuromuscular diseases prior to clinical trials.  For several complex and rare 
neuromuscular disorders, there is no accepted animal model, a lack that has stymied 
therapeutic development.   
 Facioscapulohumeral muscular dystrophy (FSHD) is one such complex 
neuromuscular disorder affecting approximately 4-7 per 100,000 individuals (48). 
Weakness in the muscles of the face, scapular region, and arms typically begins in late 
adolescence and early adulthood; however, there is a range of severity from infant to late 
adult onset, loosely correlating to genotype. The disorder is relentlessly progressive, 
eventually affecting most skeletal muscles and resulting in the lack of ability to smile, to 
raise arms overhead, and to lift.  Approximately one third of patients with FSHD lose the 
ability to ambulate.  
 The pathogenesis of FSHD has remained elusive.  The disease is due to a loss of 
macrosatellite repeats on chromosome 4q (49, 50).  Within this region, there are 3.3 kb 
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hypermethylated repetitive DNA segments termed D4Z4 repeats.  Unaffected people 
have >100 copies of D4Z4 units, while those with FSHD have 1-10 units (51).  Although 
the genetics and pathophysiology are yet to be fully elucidated, the chromosome 4q 
deletion, when it occurs in the appropriate context, appears to lead to the misexpression 
of a transcription factor DUX4-fl, which in turn activates a number of other genes (23, 
52, 53).  Due to the complexity of this epigenetic disorder, there is no accepted animal 
model of FSHD that recapitulates the disease, and there are no current ongoing clinical 
trials in the disorder.   
In cancer research,  xenografts of human tumors in immunocompromised mice have been 
used successfully to predict their clinical response to therapeutic drugs (54, 55).  Previous 
attempts to use xenografts to model muscle disease by injecting dissociated human myoblasts into 
injured mouse muscle have produced low engraftment of human cells, mainly in a perifascicular 
position (39, 56-58). However, grafts of whole muscle from the mdx mouse placed into normal 
mice retained the dystrophic phenotype of the donor mouse (59).  This finding encouraged us to 
investigate whether human muscle could be similarly grafted into immunodeficient mice and 
recapitulate key features of normal and diseased human muscle for preclinical therapeutic studies.   
 
Results 
Regeneration of human skeletal muscle in immunodeficient mice 
Human volunteers donated biceps muscle specimens through a protocol approved by the 
Johns Hopkins Medicine Institutional Review Board.  The donor muscle was trimmed 
and transplanted into the anterior compartment of the hindlimbs of immunodeficient 
NOD-Rag1nullIL2rγnull  mice in place of the host tibialis anterior and extensor digitorum 
longus muscles and sutured to the proximal and distal tendons of the peroneus longus as 
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described in Methods (see Supplementary Fig. 1).  Such grafts were spontaneously 
vascularized and survived through 36 weeks post-transplantation (Fig. 2.1A).  Myofibers 
of donor muscle degenerated and nascent fibers regenerated within the existing basal 
lamina of the donor specimen (Fig. 2.1B-E).  Regenerated fibers showed the predominant 
peripheral relocation of nuclei characteristic of  human but not murine muscle 
regeneration(60) (55 + 3% central nucleated fibers at day 14 versus 21 + 3% central 
nucleated fibers at day 140, mean + sd, n = 3 for each, p<0.001 by two-tailed t-test).  
Beyond 90 days post transplantation, grafts were fully regenerated with predominantly 
peripheral nuclei and stable average cross sectional areas (CSA) approximately one half 
that of myofibers in the donor biopsy from which they originated (1348 + 966 µm2 
versus 3382 + 945 µm2, mean + sd) (Fig. 2.1F).  
Xenografts were composed entirely of myofibers uniformly expressing human 
membrane proteins such as spectrin (Fig. 2.2A).  Multi-labeling immunohistochemistry 
(see Methods and Supplementary Fig. 2.2) was used to identify total human nuclei, 
human myonuclei and human myogenic precursor cells, satellite cells.  Within the 
xenograft area as defined by positive anti-human spectrin reactivity, 91.4 ± 3.4% of all 
nuclei, 95.2 ± 3.2% of all myonuclei and 90.2 ± 4.0% of all satellite cells were human 
(mean + sd),(Fig. 2.2B).  Capillaries within the xenograft were both human and mouse in 
origin with some appearing to be anastomoses of human and mouse capillaries (Fig. 
2.2C).  Mouse erythrocytes within capillaries indicate patency of the human vasculature 
within the xenograft (Fig 2.2D).   
 
Functional competency of skeletal muscle xenografts 
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Having established the xenograft as a feasible model of human muscle, containing 
predominantly human myofibers and nuclei, we sought evidence of functional 
competence.  As described in Methods, the graft of human biopsy sample was sutured to 
the peroneus longus muscle overlying a branch of the peroneal nerve (freed after tibialis 
resection).  Figures 2.3A and 2.3B reveal neuromuscular junctions (NMJs) in 
cryosections of xenografts indicating innervation of the xenograft.  Furthermore, the 
presence of both type 1 and type 2 fibers (Fig. 2.3C) indicate re-innervation by more than 
one motor neuron.   
While the graft is innervated, in situ or in vivo assessment of xenograft function 
could not be technically differentiated from function of the host peroneus longus to which 
it was sutured.  Graft specific contractility was assessed in explanted xenografts in vitro 
with trains of action potentials (APs) delivered with increasing frequency (i.e. force 
frequency response) (61-63).  The xenograft exhibited a steep force frequency response 
indicative of functionally competent muscle (Fig. 2.4A and 2.4B). Functional 
assessments were also made on intact, single myofibers enzymatically isolated from 
xenografts and verified as human in origin (Fig. 2.4C) (62, 64).  Myofibers were loaded 
with the Ca2+ indicator dye Indo-1-PE and stimulated to contract with electrical field 
pulses.  The presence of robust responses to brief single pulses or tetanic trains of pulses 
(Fig. 2.4D and 2.4E) indicate a fully competent excitation-contraction (EC) coupling 
system in these fibers.  
A xenograft model of Facioscapulohumeral muscular dystrophy  
To test the suitability of the xenograft as a model for muscle disease, we grafted 
mildly weak muscle from subjects with FSHD into the anterior compartment of NOD-
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Rag1nullIL2rγnull  host mice.  Biceps muscle was donated from families (cohort numbers 
29, 30, 33 and 37) with affected (indicated by letters, “A”, “B” or “C”) and unaffected 
(indicated by letter “U”) members to serve as close genetic controls(65).  Muscle from 
FSHD individuals, as well as unaffected family members, regenerated in 
immunodeficient mice (Fig. 2.5A).  DUX4-fl expression, assayed by nested RT-PCR, 
was detected in xenografts which originated from FSHD affected muscle donors but not 
in xenografts which originated from control unaffected donors (Fig. 2.5B).   
We next assessed whether the gene expression differences between FSHD and 
control biopsies were also present in FSHD versus control xenografts. Probably because 
they have passed through a round of degeneration and regeneration, grafted muscles 
showed not-unexpectedly different baseline gene expression levels from human biopsies. 
However, the ordinal levels of expression of FSHD and control biopsies are concordant 
with those observed between FSHD and control xenografts derived from these biopsies. 
These comparisons were made between xenografts derived from 5 individuals from 2 
families (see Methods). We measured expression levels for a panel of 25 genes in 22 
xenograft samples, and the 5 human biopsies of origin with real-time quantitative PCR 
(qPCR).  This panel consisted of: 15 genes identified as differentially expressed in a 
microarray study of FSHD versus control biopsies(66), 8 genes (MBD3L5, PRAMEF1, 
PRAMEF6, SLC34A2, SPRYD5, TRIM43, TRIM49, ZSCAN4) that are dramatically 
upregulated by ectopic overexpression of DUX4-fl in cell-cultures(67), and PPIA and 
GUSB, which were used for normalization.  
Expression differences in FSHD versus control xenografts were compared with 
the differences between the FSHD and control biopsies from which they had been 
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derived; this was performed separately for three pairs of affected and unaffected 
individuals within a family (Supplementary Fig. 2.3). In each case, the log2(fold-changes) 
for FSHD vs. control of the xenografts was strongly concordant with those of their 
biopsies of origin (Pearson correlation 0.63, 0.89, 0.66 respectively; p < 0.001 for each). 
For two of the three comparisons, there was a significant agreement in the direction of the 
changes (i.e., the sign of the log2(fold-changes);  p = 0.07, p = 0.002, p = 0.0004 
respectively by Fisher’s exact test). Most of the genes with discordant direction of change 
had log2(fold-changes) close to zero. The consistency of the relationship between biopsy 
and xenograft is epitomized by the finding that the strong upregulation of MYH8 reported 
in a larger FSHD collection(66) was not seen in either the biopsy, or the corresponding 
xenografts of FSHD individuals 33A and37B, but was seen for both the biopsy and 
xenografts of 33C (Fig. 2.5D and Supplementary Fig. 2.3).  
Although the xenografts in the gene expression analysis were derived from a 
small population of biopsies (3 FSHD and 2 control), it is encouraging that the 
differences in FSHD versus control samples from the pooled xenografts not only have 
good agreement with the differences between the pooled biopsies from which they were 
derived (Fig. 2.5C; Pearson correlation 0.87; p =2e-08 for correlation test; p = 0.003 for 
agreement in direction of changes by Fisher’s exact test), but also reflect the FSHD-
related differences reported in larger populations of unrelated samples: upregulation of 
MYH8 (albeit mild, for the reasons discussed above) and downregulation of EXTL1, 
G0S2, GLT25D2, IDI2, and TECRL (66), and upregulation of the DUX4-induced genes 
MBD3L5, PRAMEF1, PRAMEF6, SLC34A2, SPRYD5, TRIM43, TRIM49,  and 
ZSCAN4(67).  Figure 2.5D highlights the genes with the strongest down-regulation and 
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up-regulation in the pooled FSHD versus control biopsies (EXTL1 and TRIM49) and 
xenografts (IDI2 and ZSCAN4), excluding those genes that were not detected in all 
samples. 
 
Autopsy skeletal muscle specimens as donors for xenografting 
Recognizing that many laboratories will not have easy access to fresh 
muscle biopsy tissues, we evaluated whether autopsy material could be similarly 
used as donor muscle.  Autopsy material from the biceps of an octogenarian with 
FSHD was transplanted into immunodeficient mice approximately 48 hours after 
death of the donor.  This autopsy specimen, which was neither ideal in age of donor 
nor time from death to transplantation, regenerated well in the NOD-Rag1null 
IL2rγnull host. Since satellite cells have been shown to survive for many days in 
postmortem muscle (68) this new model might be easily generated by other 
laboratories (Supplementary Fig. 2.4). 
 
Discussion 
Our results establish the feasibility of grafting human muscle into 
immunocompromised mice, where it regenerates, becomes innervated, and displays 
functional contractility.  The grafted muscle retains human characteristics including the 
peripheral migration of centralized nuclei during regeneration.   The xenograft may, 
therefore, provide a unique opportunity to study human muscle regeneration over time 
with a degree of access and invasive experimental scrutiny that is not available in human 
subjects.  A limitation of the model in this regard is the requisite immunodeficiency of 
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the host mice, in our study NOD-Rag1null IL2rγnull , which lack functional T cells, B cells, 
and Natural Killer cells (69). More directly important to muscle regeneration than 
lymphocytes, however, are macrophages that in NOD-Rag1null IL2rγnull appear to be 
present, although reduced in number (69).  
For muscular dystrophies without animal models, or with suboptimal animal 
models –which is true to some extent with all of them – the human muscle xenograft will 
be a useful new preclinical tool.  FSHD is a complex genetic disorder for which the 
relative lack of clinical trials is attributable in part to the absence of an accepted mouse 
model for preclinical testing.  Each of the proposed animal models of FSHD has its own 
distinct strengths and weakness. One early mouse model transgenically overexpressed 
FRG1, which previous studies had shown was increased in expression in FSHD patient 
derived muscle biopsies (15). Although the model exhibits skeletal muscle pathology, the 
failure of subsequent studies of muscle biopsies from FSHD individuals to replicate the 
misexpression of FRG1 (66, 70) raises questions about the validity of this mouse.  
Conditional expression of DUX4 in zebrafish produces an intriguing constellation of eye, 
ear, and muscle abnormalities reminiscent of FSHD (71), however a conditional model of 
DUX4 expression in mice is not yet available in that constitutive expression of DUX4 is 
toxic to cells (72, 73). More recently, a mouse model has been developed carrying the 
FSHD permissive subtelomeric region and demonstrating DUX4 transcripts in multiple 
tissues including skeletal muscle (33).  This will be a useful model to study de-repression 
of DUX4, but as the lack of muscle pathology in this model suggests, it may not be as 
helpful in studying pathogenesis downstream from DUX4, which necessarily depends on 
mouse genes.  The xenograft model described in this paper also has limitations; namely, 
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an inability to assess whole animal function such as grip strength or treadmill endurance.  
Since the xenograft expresses genes mirroring the human muscle from which it 
originated, we anticipate that it will be especially useful for studies with molecular 
outcomes (such as gene replacement or silencing studies).  
In general, for detailed cell and molecular biology investigation of human muscle, 
investigators have resorted heavily to tissue culture for short-term ex-vivo maintenance 
of human muscle. However, even superficial assessment tells us that this is remote in 
many ways from functional muscle in vivo. At the molecular level, too, tissue culture can 
be deceptive. For example  exon skipping studies in the dystrophic GRMD dog and the 
mdx mouse reveal that data from tissue cultures do not provide a reliable guide to in vivo 
behavior (74, 75). The graft procedure we have described here should not only be 
applicable to genetic diseases of muscle for which we lack suitable animal models but 
should also hold promise for gaining a more detailed understanding of a number of 
acquired muscle conditions.  The vigor of regeneration of our autopsy graft from an 
octogenarian donor opens new avenues into the study of the effects of age and disease on 




Materials and Methods 
Human muscle acquisition  
This study was approved by The Johns Hopkins School of Medicine Institutional Review 
Board. Subjects with FSHD and their first degree unaffected relatives, were recruited and 
screened for biomaterial contributions. Subjects had their FSHD genetic status confirmed 
by the University of Iowa Diagnostic Laboratories by pulse-field gel electrophoresis 
(PFGE) and Southern blotting as previously described (65). Subjects were categorized as 
“affected” (and labeled “A”, “B” or “C”) if they had contraction of the D4Z4 array (fewer 
than 11 repetitive units) associated with the 4qA allele and “unaffected” (and labeled 
“U”) if they had no contraction.  Open muscle biopsy was performed on biceps muscles 
having strength greater than 4- out of 5 (MRC scale). A portion of the harvested tissue 
was dissected into several small strips of longitudinal fibers approximately 1 cm long and 
taken immediately to the animal suite for xenografting.  
 
Surgical procedure  
The Institutional Animal Care and Use Committee at the Johns Hopkins University 
School of Medicine approved the animal and surgical procedures performed in this study. 
Female NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ immunodeficient mice (The Jackson 
Laboratory) were used for this study. Donor human muscle was trimmed to 8 mm x 3 
mm x 1 mm strips. Host mice were anaesthetized with isofluorane. The tibialis anterior 
and extensor digitorum longus were removed from the anterior tibial compartment. The 
neurovascular bundle was severed leaving maximal length. A strip of human muscle was 
placed in the empty anterior compartment and ligated with nonabsorbable suture (6/0 
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POLYPRO, CP medical) to the tendons of the peroneus longus. Skin was closed with 
surgical glue (Histoacryl, B. Braun) and stainless steel wound clips (Reflex Wound Clips, 
CellPoint Scientific). Rimadyl 5mg/kg was given subcutaneously after the surgery for 
pain control.  
Immunohistochemistry and morphometric analysis  
Mice were sacrificed at a variety of time points up to 36 weeks post transplantation. The 
graft was harvested with the entire mouse lower limb, frozen, and serially sectioned as 
previously described (76).  Ten micron cryosections were stained with H&E or processed 
for immunohistochemistry. Ice-cold methanol fixed sections were blocked with anti-
mouse IgG (MKB-2213, Vector Laboratories). The primary antibodies used were anti-
human spectrin (NCL-SPEC1, Leica, 1:50 ), anti-human collagen IV (M3F7, DSHB, 
1:50), anti-human lamin A/C (Ab40567, AbCam, 1:200), anti-synaptic vesicle 2 (SV2, 
DSHB, 1:50), anti- type I myosin heavy chain (A4.840, DSHB, 1:50), anti-type II myosin 
heavy chain (A4.74, DSHB, 1:50), anti-human CD31 (M0823, DAKO, 1:20), anti-mouse 
CD31 (550274, BD, 1:50), anti-mouse TER-119 (550565, BD, 1:50), anti-human laminin 
(2E8, DSHB, 1:100), anti-Pax7 (PAX7, DSHB, 1:10). The secondary antibodies used 
were AlexaFluor 488 goat anti-mouse IgG1, AlexaFluor 594 goat anti-mouse IgG2b, 
AlexaFluor 647 goat anti-mouse IgM and AlexaFluor 594 goat anti-rat IgG (all 
Invitrogen, 1:500). Tetramethylrhodamine α-Bungarotoxin (T-1175, Invitrogen, 1:50) 
was used for detecting postsynaptic membranes. All nuclei were labeled with DAPI in 
mounting medium (P36930, Invitrogen). Image capture was performed using an upright 
microscope for brightfield, DIC, and epifluorescence with apotome structured 
illumination digital imaging system (Zeiss). The image stacks consisted of 6 optical 
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sections with 1.4-μm Z-steps. Nuclei staining positive for DAPI but outside anti-human 
laminin were considered interstitial cells while those inside laminin were considered 
myonuclei. Satellite cells were identified by Pax7+ staining within anti-human laminin 
staining. Muscle fiber cross-sectional areas were determined by using Scio Image 
Software (NIH) on anti-human spectrin stained sections as previously described(77). 
Central nucleated fibers were counted in anti-human spectrin and lamin A/C  positive 
regions as previously described(78).  
 
 
In vitro functional assessment  
Grafts were carefully dissected away from the mouse peroneus longus muscle belly and 
affixed at the suture sites. Following equilibration, the force vs. frequency relationship 
was evaluated as previously described (61). Peak isometric tension was normalized to the 
calculated cross-sectional-area using the length (mm) and mass (mg) of the muscle 
between the sutures.  
Single intact myofibers were enzymatically isolated from the xenograft using 
Collagenase A (Roche) in DMEM and adhered to glass-bottom imaging dishes as 
described previously (61, 64, 79).  Myofibers were loaded with the dual emission, 
ratiometric, fluorescent Ca2+ indicator, Indo-1 PE AM (5 μM in 20% pluronic/DMSO), 
for 45 min in a normal rodent Ringer (in mM: 140 NaCl, 4 KCl, 1.8 CaCl, 1 MgSO4, 5 
NaHCO3, 10 HEPES, 5 glucose, pH 7.4). Dishes were washed and incubated for 30 min 
in Ringer to allow Indo-1 deesterification. Myofibers were imaged on an IonOptix dual 
PMT imaging platform mounted to an IX-70 inverted fluorescence microscope (40x 
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water UV objective) equipped with a Sutter DG-4 excitation source (excitation: 340+/- 10 
nm). The Indo-1 PE emission ratio (emission: 405/485 nm, sampled at 1KHz) was taken 
as the estimate of myoplasmic Ca2+ concentration ([Ca2+]). The Indo1 ratio was assessed 
in quiescent myofibers to determine the resting myoplasmic [Ca2+]. Action potential 
induced fluorescent transients were elicited with brief (200µsec, square pulse) trains of 
pulses delivered at 10 or 100 Hz.   
 
FSHD xenograft DUX4-fl expression  
Total RNA was isolated from frozen muscle biopsy samples and xenografts using Trizol 
(Invitrogen) and RNeasy mini kit (Qiagen). DUX4-fl expression was determined using 
100 ng of poly(A)+ cDNA by a nested reverse transcription polymerase chain reaction 
(RT-PCR) as described previously (25). PCR products were sequenced and specificity of 
reaction products was confirmed.  
Gene expression analysis 
High-throughput real-time qPCR was performed on the BioMark 96.96 Dynamic Array 
(Fluidigm) with TaqMan Gene Expression Assays (Applied Biosystems), as previously 
described (66). Gene expression analyses were done on xenografts derived from 5 
individuals from 2 families: FSHD subjects 33A, 33C and control subject 33U from 
family 33 (previously reported (66)), and FSHD subject 37B and control subject 37U 
from family 37. There were six xenograft samples derived from the biceps of 33C, and 
four xenograft samples derived from the biceps of each of the other four individuals.  
We tested whether the TaqMan primers for the 25 assayed human genes (assay 
IDs listed in Supplementary Table 1) were specific to human as opposed to mouse 
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mRNA by including two samples of tibialis anterior muscle from non-xenograft mice 
(TA1 and TA2).  CAB39L and OXCT1 were detected in these samples, with raw Cts 
(threshold cycles) 18 and 32 respectively, but the other 23 genes were not. The raw Cts 
for the xenograft mice averaged 15 for CAB39L and 17 for OXCT1. As the value for 
OXCT1 in xenografts is 15 Ct lower (suggesting 215 ≈ 30,000 times greater signal) than in 
the non-xenograft mice, the signal for it in xenografts should be largely from human 
mRNA. For CAB39L, the difference is ~3 Ct, so mouse mRNA levels may potentially 
partially mask differences in human mRNA levels in the xenografts.   
 
Statistical Analysis  
The raw Ct value for each gene for each sample was computed as the median value of the 
Cts from three technical qPCR replicates. These values are given in Supplementary Table 
2. Sample names are in the top row: names with prefix “biop” are biopsies (biceps) from 
the indicated subject, those with prefix “xg” are xenografts derived from the indicated 
subject (with mouse index number and L/R leg as a suffix), and TA1 and TA2 are the 
non-xenograft mouse controls. ND indicates that the gene was not detected in the sample.  
To account for differences in quantities of input RNA for each sample, and in the 
case of xenografts for differences in relative abundances of human vs. mouse RNA, raw 
Cts were normalized to ΔCt values by subtracting the mean Ct of PPIA and GUSB, which 
were previously identified as stable internal controls genes(66). 
Estimates of log2(fold-changes) for FSHD/control comparisons would typically be 
computed as the mean ΔCt for control samples minus the mean ΔCt for FSHD samples, 
but because many of the DUX4-induced genes are near the qPCR detection threshold 
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(where the variance increases sharply and genes may not be detected in some samples) 
we first performed a variance-stabilizing transformation (vst) on the ΔCt values. 
Modeling the standard deviation as independent of the mean for ΔCt < 5 (corresponding 
roughly to raw Ct < 20) then increasing linearly by 25% of the baseline standard 
deviation per additional Ct, by the delta method the asymptotic variance-stabilizing 
transformation is given by vst(x) = , so vst(x) = x for x ≤ 5 
and vst(x) = 5 + 4(ln(x - 1) - ln(4) ) for x > 5. To avoid infinite fold-changes, non-detected 
genes were assigned the value ΔCt = 25 (approx. 1 Ct higher than the highest value for 
any detected gene in any sample) prior to applying the vst; these genes are indicated by 
special symbols in Figure 5 and Supplementary Figure 3. The tests for significant 
differences between FSHD and control xenografts for individual genes used non-
parametric Wilcoxon rank-sum tests, so were not affected by the monotonic vst or by the 
precise choice of value assigned to the non-detected genes, which are regarded as tied for 
having the highest Ct value. These tests used the function wilcox.exact in the R package 
exactRankTests, which allows for tied observations. 
For the simple pairwise comparisons (33A vs. 33U, 33C vs. 33U, 37B vs. 37U), 
log2(fold-changes) were computed from mean values of variance-stabilized ΔCt values. 
For the pooled comparisons of all FSHD vs. all control, as there were differences in the 
number of individuals per family (three from family 33 and two from family 37) and the 
number of xenograft mice per individual (six for 33C; four for the others), we used 
mixed-effect models to compute the log2(fold-changes) from the variance-stabilized ΔCt 
values. For humans this model had a fixed effect for Class (FSHD vs. control) and a 
random effect for Family (model specification vst.values ~ Class + (1 | Family) in R 
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package lme4). For xenografts, the model also included blocking factors for replicate 
mice derived from the same individual (model specification vst.values ~ Class + (1 | 
Family) + (1+ Class | Individual)). Tests for agreement in direction of expression changes 
used Fisher’s exact test (fisher.test in R, one tailed) on the 2×2 contingency tables of gene 
counts, with the sign of the log2(fold-change) in xenografts in one margin and the sign of 
the log2(fold-changes) in biopsies in the other margin. Genes were excluded if their 
log2(fold-change) was exactly zero in either margin, which happened only for genes that 







Figure 2.1. Human muscle regenerates in immunodeficient NOD-Rag1null  
IL2rγnull mice. (A) Human muscle graft at 130 days post-transplantation into mouse 
hindlimb. Black sutures indicate ends of graft. (B) Hematoxylin and eosin (H&E) stained 
cross-section of original donor biceps biopsy. (C) H&E stained cross-section of human 
graft at 14 days post-transplant. Large myofibers continue to degenerate (arrow) and 
clusters of small myofibers regenerate (arrowhead and box) within original myofiber 
basal lamina (insert, anti-human spectrin in red, anti-human collagen IV in green). (D) 
H&E stained cross-section of human graft at 60 days demonstrating increasing size of 
grouped myofibers. Asterisk indicates neighboring host mouse muscle. (E) H&E stained 
cross-section of host hindlimb with fully regenerated human graft at 130 days. Graft 
within dotted lines.  Asterisk indicates mouse muscle.  Scale bars, 200 µm. (F) 
Histograms of cross sectional area (CSA) of myofibers from xenograft at 130 days (left) 




Figure 2.2. Skeletal muscle xenografts have human myofibers, nuclei and capillary 
immunoreactivity. (A) Anti-human spectrin antibodies (red) define discrete boundaries 
(insert) of xenograft (serial section of 1E) from neighboring mouse muscle (asterisk) and 
uniformly recognize myofiber membrane. Scale bar, 200 µm. (B) Within anti-human 
spectrin defined xenograft, 91.6 ± 5.3% of all nuclei (DAPI+), 92.4 ± 3.8% of myonuclei, 
and 90.1 ± 3.8% of Pax7+ satellite cells are human as recognized by anti-human lamin 
A/C. (n = 6). Data are shown as the mean ± sd. (C) Both human (green) and mouse (red) 
vascular networks were identified with species-specific CD31 antibodies, which appear 
to anastomose (insert). Scale bar, 200 µm. (D) Human capillaries (green) within the 
xenograft contain mouse erythroid cells identified with species-specific antibodies (red). 





Figure 2.3. Xenografts are innervated. (A) Cross-section and (B) longitudinal section 
of 130-day xenografts demonstrate co-localization of presynaptic anti-SV2 reactivity 
(green) and postsynaptic α-bungarotoxin reactivity (red). Scale bars, 20 µm. (C) 
Immunohistochemistry demonstrates both type I (purple) and type II (green) myofibers in 
mature xenograft with a predominance of type I fibers. Asterisk indicates mouse muscle. 
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Scale bar, 200 µm. 
 
 
Figure 2.4.  Xenografts are functionally competent. (A) Xenograft explants were 
suspended in a temperature-controlled, physiological saline contained bath and 
electrically-evoked force measurements were recorded with 250msec trains of pulses 
delivered between 1-300Hz. Representative isometric force traces are shown normalized 
to the calculated cross-sectional area of the xenograft. (B) Force-frequency relationship of 
aggregate data from 3 xenografts derived from 3 healthy donors. (C) Single 
enzymatically isolated myofiber from xenograft identified post-physiology as human with 
immunohistochemistry using anti-human spectrin (red), anti-human lamin A/C (green) 
antibodies and DAPI (blue). (D) Single myofibers were loaded with the ratiometric 
calcium (Ca2+) dye Indo-1PE and electrically stimulated to elicit calcium transients. 
Representative twitch (single square 0.2usec square field pulses, black trace) or tetanic 
trains (100Hz, blue trace) are shown from fibers isolated from xenograft explants (n=3) of 
healthy donors. (E) Aggregate Ca2+ transient data (Box whisker plot; box = 5-95%; line 





Figure 2.5. Validation of the model for FSHD. (A) H&E stained section (left) of FSHD 
xenograft next to host mouse peroneus (asterisk) at 140 days, human muscle fibers 
identified by anti-human spectrin (right, red). (B) DUX4-fl mRNA is specifically 
expressed in xenografts from FSHD muscle biopsies. Polyadenylated DUX4-fl mRNA 
expression was analyzed by RT-PCR in xenograft muscle originating from FSHD and 
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control biopsy. Expression of DUX4-fl mRNA in the original muscle biopsy specimen 
was similarly assayed by RT-PCR, and DUX4-fl mRNA expression in the 29A muscle 
biopsy was confirmed previously (25). All RT-PCRs were repeated at least three times. 
All products were sequenced to confirm the presence of spliced DUX4-fl mRNA (arrow) 
in samples from FSHD1 xenografts (29A, 30B, 37A and 37B) and FSHD1 biopsy (30B, 
37A and 37B). RT–PCR for GAPDH mRNA expression controlled for integrity of the 
mRNA and first strand cDNA synthesis. (C and D) Expression differences between 
FSHD and control biopsies are correlated with expression differences in the xenografts 
derived from these biopsies. In (C), log2(fold-changes) for FSHD vs. control biopsies 
(horizontal axis) are plotted against the corresponding log2(fold-changes) for FSHD vs. 
control xenografts (vertical axis) for the 25 genes assayed by qPCR. For both axes 
positive values represent higher expression in FSHD samples than control samples. The 
log2(fold-changes) were fit using mixed-effect models on variance-stabilized normalized 
Ct values for 5 individuals (3 FHSD, 2 control) from 2 families, and 22 xenografts 
derived from these individuals (see Methods). The log2(fold-changes) for lowly 
expressed genes may be compressed due to the variance stabilization, and log2(fold-
changes) should be regarded with particular caution for genes represented by triangles 
(not detected in at least one xenograft) and squares (not detected in at least one xenograft 
and at least one biopsy. Dashed black line: perfect agreement; dashed red line: best fit 
using orthogonal regression. In (D), ΔCt values are shown for five genes: TRIM49, 
ZSCAN4, EXTL1, IDI2, and MYH8. Each column represents a biopsy subject, with 33U 
repeated to clarify its relation to both 33A and 33C.  Meanings of colors and symbols are 
defined in figure. Upward sloping lines indicate higher expression (lower ΔCt) in the 
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FSHD sample than the control. Solid and dashed lines between two subjects slope in the 
same direction when xenografts display the same direction of difference as the biopsies 




Supplementary Data  
Figure S2.1. Human muscle transplanted to mouse limb: surgical procedure. (A) With 
the mouse hair removed on the lower hindlimb, and skin cleansed, an incision is made 
overlying the tibialis. (B) Graft site is created by complete excision of the host tibialis 
anterior and extensor digitorum longus. Sutures (shown proximally with black thread) are 
looped around the peroneus longus tendons. (C) Donor graft is implanted into the site and 
tied to the proximal and distal tendons of peroneus longus muscle. (D) The skin over the 




Figure S 2.2. Human muscle regenerates and survives through 41 weeks post-
transplantation. (A) H&E staining of the xenograft harvested 41 weeks after 
transplantation. (B) Immunohistochemistry of a serial section with anti-human spectrin 
(red), anti-human lamin A/C (green) and DAPI (blue). Asterisk indicates host mouse 




Figure S 2.3. Identification of various types of human nuclei in the xenograft by 
immunofluorescence. Immunohistochemistry of cross-section of xenograft 120 days post-
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transplantation.   (A) Anti-human lamin A/C identifies all human nuclei (red). (B) Anti-
pax7 (green) identifies satellite cells. (C) Anti-human laminin identifies basal lamina 
(purple). (D) Merge image with DAPI (blue). Three types of human nuclei can be 









Figure S2.4. Pairwise expression differences between FSHD and control biopsies are 
correlated with expression differences in the xenografts derived from these biopsies. 
Nomenclature: 33A, 33C and 33U are individuals from the same family where 33A and 
33C are FSHD affected, and 33U is unaffected, confirmed by 4qA allele genotyping.   
Similarly, 37B and 37U are individuals from a different family where 37B is affected and 
37U is unaffected. Each subplot shows log2(fold-changes) for a pairwise FSHD vs. 
control biopsy (horizontal  axis) plotted against the corresponding log2(fold-changes) for 
FSHD vs. control xenografts derived from these biopsies (vertical axis) for the 25 genes 
assayed by qPCR: at top is 33A vs. 33U, in the middle 33C vs. 33U, and at bottom 37B 
vs. 37U. For both axes, positive values represent higher expression in FSHD samples 
than control samples. Genes in the upper-right and lower-left quadrants show consistent 
direction of change for biopsies and xenografts. The log2(fold-changes) for xenografts 
are differences in means of variance stabilized normalized Ct values for multiple FSHD 
and control xenografts (n = 6 for 33C, n = 4 for others). Genes are colored green if the 
FSHD and control xenografts differ at p < 0.05 by the Wilcoxon rank-sum test. 
(Statistical tests are not done for the biopsies as there is just one FSHD and one control 
sample in each comparison.) The log2(fold-changes) for lowly expressed genes may be 
compressed due to the variance stabilization, and log2(fold-changes) should be regarded 
with particular caution for genes represented by triangles (not detected in at least one 
xenograft) and squares (not detected in at least one xenograft and at least one biopsy), for 
which non-detected transcripts were assigned Cts near the detection limit (see Methods). 
The dashed diagonal black line indicates perfect agreement and the dashed red line is the 






Figure S2.5. Human muscle xenograft generated from muscle sample harvested 48 hours 
postmortem. (A) H&E staining of the autopsy generated xenograft 110 days after 
transplantation. (B) Immunohistochemistry of a serial section with anti-human spectrin 
(red), anti-human lamin A/C (green) and DAPI (blue). Asterisk indicates host mouse 




Table S 2.1. TaqMan Gene Expression assays from Life Technologies 
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Derepression of DUX4 in skeletal muscle has emerged as a likely cause of pathology in 
facioscapulohumeral muscular dystrophy (FSHD). Here we report on the use of antisense 
phosphorodiamidate morpholino oligonucleotides (PMOs) to suppress DUX4 expression 
and function in FSHD myotubes and xenografts. The most effective was PMO FM10, 
which targets the polyadenylation signal of DUX4. FM10 had no significant cell toxicity, 
and RNA-seq analyses of FSHD and control myotubes revealed that FM10 down-
regulated many transcriptional targets of DUX4, without overt off-target effects. 
Electroporation of FM10 into FSHD patient muscle xenografts in mice also down-
regulated DUX4 and DUX4 targets. These findings demonstrate the potential of antisense 







FSHD1 and 2 are genetic diseases whose primary manifestations are weakness and 
wasting of muscles of the face, shoulder girdle and upper arms. FSHD1, representing 
~95% of cases, is associated with deletions of macrosatellite D4Z4 repeats in the 
subtelomeric region of chromosome 4q35, leaving 1-10 D4Z4 repeats (80). FSHD2 is in 
most cases associated with mutations in SMCHD1 on chromosome 18 (81). Both of these 
mutations lead to relaxation of chromatin at the 4q35 D4Z4 repeat array, allowing 
aberrant transcription in muscle of a full-length form of DUX4 mRNA (DUX4-fl), which 
encodes a double homeobox transcription factor (23, 81-84). Development of laboratory 
animal models of FSHD have been challenging, due in part to the unknown 
pathophysiologic mechanism of DUX4 action and the restricted emergence of the D4Z4-
DUX4 chromosomal architecture in primates and Afrotheria (6, 85). Nevertheless, the 
evidence that DUX4 is an FSHD disease gene is compelling, including the findings that: 
(1) both FSHD1 and 2 are associated with particular “permissive” 4q35A haplotypes that 
include a polyadenylation signal required for production of stable DUX4-fl mRNA from 
the telomeric D4Z4 repeat; (2) overexpression of DUX4-fl induces a large cohort of 
germline genes that are also up-regulated in FSHD muscle (67, 83, 86); and 3) 
overexpression of full-length DUX4 protein is toxic in muscle, both in vitro and in vivo 
(24, 87).   
These findings identify DUX4 as a promising therapeutic target for antisense 
therapy.  Antisense oligonucleotides (AONs) are being developed as therapeutics for 
other neuromuscular diseases including Duchenne muscular dystrophy (DMD), spinal 
muscular atrophy (SMA) and myotonic dystrophy (88-91). Here we report a proof-of-
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concept study of the therapeutic potential of antisense phosphorodiamidate morpholino 
oligonucleotides (PMOs) for the treatment of FSHD, by targeting DUX4 and 





Results and Discussion 
 Transcriptome sequencing (RNA-seq) was performed on cultured myotubes 
derived from the biceps of 6 FSHD subjects and their unaffected first-degree relatives to 
establish a reference transcriptional signature (Fig. 3.2A, Table S 3.1). Consistent with 
previous studies (86), FSHD myotubes expressed elevated levels of direct and indirect 
transcriptional targets of DUX4 (67). The mRNA levels of DUX4 targets serve as 
biomarkers of DUX4 activity, and can be more readily quantified than levels of DUX4 
mRNA or DUX4 protein, which are often quite low (67). 
 PMOs that target the DUX4-fl transcript (Fig. 3.1A; Table S 3.2) were tested for 
their ability to suppress the expression of DUX4 protein and selected DUX4 target genes 
(92-94). Differentiating myotube cultures derived from FSHD subjects were treated for 
four days with control or DUX4 PMOs, and then analyzed for biomarker expression to 
assay knockdown efficiency. FM10 and, to a lesser extent, FM9 had the greatest effects, 
consistently decreasing levels of DUX4 target genes ZSCAN4, MBD3L2, and TRIM43 
(Fig. 3.1B; Fig. S 3.1), establishing that these compounds block DUX4 function. Both 
FM10 and FM9 target the polyadenylation signal region of the DUX4 transcript. In 
contrast, other PMOs tested in this series did not decrease biomarker expression. Notably, 
PMOs did not disrupt expression of myosin heavy chain, a marker of myogenic cell 
differentiation. FM10 down-regulation of DUX4 target genes in FSHD cells was dose-
dependent, with ED50 in the range from 1-3 uM, and maximal response between 10 and 
20 uM, without evidence of cell toxicity (Figs. S 3.2, S 3.3).  
 PMO effects on protein levels of DUX4 were evaluated in control and DUX4 
PMO-treated FSHD myotube cultures by immunostaining with an antibody targeting a C-
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terminal region in the full-length DUX4 protein that is absent from the alternatively 
spliced “short” DUX4, which is not thought to be a toxic protein (83). DUX4-positive 
nuclei were reduced in FM9-treated myotubes and almost undetectable in FM10-treated 
myotubes (Fig. 3.1C), establishing their inhibition of DUX4 protein expression.  
 Transcriptomes of FSHD and control myotube cultures treated with FM10 or 
standard control PMO were determined by RNA-seq, using p < 10-4 as the cutoff for 
significance to control for the number of false positives. In myotube cultures from two 
FSHD subjects, 47 genes differed significantly between FM10 versus control PMO 
treatment, with an associated false discovery rate (FDR) of 0.066 (Fig 2B, Table S3). Of 
these 47 transcripts, 46 had lower expression with FM10 treatment than with control 
PMO.    
To assess whether these changes reflected a suppression of FSHD-associated 
transcription, we compared PMO transcriptome results to the RNA-seq data from 
myotubes of six FSHD subjects versus their unaffected relatives, in which 121 genes 
were significantly upregulated in FSHD and 5 were significantly downregulated (FDR = 
0.021; Table S 3.1), and to the 213 DUX4 targets from Table S1, Yao et al (86), which 
includes 94 of the 121 genes significantly upregulated in FSHD versus unaffected 
myotubes. Both false positives and false negatives have a stochastic component 
(including sampling error), which limits how well sets of significantly altered genes from 
different studies will agree, even for identically designed and equally powered studies 
(which these are not). As a more relaxed measure of agreement, though still subject to 
sampling error, we checked whether the significantly altered genes in one study were 
changed in a consistent direction in the other study, regardless of significance. Of the 46 
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genes that were significantly decreased by FM10, 41 showed elevated expression in 
FSHD versus control myotubes, significantly for 32, and 30 were among the DUX4 
targets from Table S3.1 of Yao et al. (86). Thus most of the genes significantly decreased 
by FM10 are elevated in FSHD.  Conversely, 116 of the 121 genes that were significantly 
elevated in FSHD versus unaffected myotubes, and 162 of the 185 detected DUX4 target 
genes from Yao et al. (86) showed at least some reduction by FM10.  The reduction was 
not typically to the level of DUX4 targets observed in control cells: many DUX4 targets 
were elevated more than 16-fold in FSHD versus unaffected myotubes (log2 fold-change 
> 4 in Fig. 3.2A), whereas few showed more than 4-fold decrease by FM10 versus 
control PMO (log2 fold-change < -2 in Fig. 3.2B), and this is not because the two FM10-
treated FSHD samples had particularly low levels of the DUX4 targets pre-treatment 
(Fig. S3.3).  
RNA-seq analysis of FM10 myotube cultures from the two unaffected first-degree 
relatives provides another view of off-target effects, unclouded by DUX4 target genes, as 
unaffected cells express little if any DUX4-fl. For these cells, only 3 genes differed 
significantly between GZ10 and the control PMO (p-value < 10-4), and this is roughly 
what one expects by chance when testing ~37,000 genes for differential expression, even 
if the null hypotheses of equal expression are all true (Fig 2C). No genes had p-value < 
10-5 or FDR < 0.72. Thus we observed no clear off-target effects of FM10 based on these 
samples. 
 We evaluated FM10 PMO knockdown of DUX4-fl in human muscle in vivo using 
an FSHD xenograft model created by transplanting FSHD affected donor muscle into the 
hindlimbs of NOD-Rag1null null immunodeficient mice (95). Engrafted muscle from 
 
 54 
FSHD biopsy donors and FSHD autopsy donors regenerated and was re-vascularized and 
re-innervated by four months post-transplant. Importantly, DUX4-fl as well as DUX4 
target gene expression in these xenografts have been shown to mirror those of the donor 
muscle tissue (95).  FM10 or standard control PMO was electroporated into FSHD 
xenografts, and mice were analyzed after two weeks (Fig. 3.3A) (95). Human xenografts 
were confirmed by immunohistochemistry using anti-human spectrin and anti-human 
lamin a/c antibodies to stain specifically for human muscle fiber membranes and human 
nuclei, respectively (Fig. 3.3B). In FSHD xenografts, FM10 reduced DUX4-fl expression 
to nearly undetectable levels compared to control PMO (Fig. 3.3C). FM10 treatment also 
reduced the expression of DUX4 target genes MBD3L5 and ZSCAN4 in xenografts 
compared to control PMO (Fig. 3.3D). 
 Our study provides proof-of-concept that antisense PMO targeted specifically to 
the essential DUX4 polyadenylation signal can significantly diminish the expression of 
DUX4-fl and DUX4 target genes that serve as biomarkers of DUX4 activity (83, 96, 97), 
both in vitro and in human xenografted muscle in vivo.  Previously, PMOs and other 
AONs targeting 3’ elements of DUX4-fl, including splice acceptor sites 2 and 3 and the 
polyadenylation signal, have been shown to reduce expression of DUX4 and select 
DUX4 targets in vitro (98, 99). Our in vitro studies provide a global view of 
transcriptional changes associated with DUX4 knockdown, and provide experimental 
data on off-target effects that complement in silico predictions. In particular, the 25 
nucleotide sequence targeted by FM10 is the same as that targeted by PMO-PAS in 
Marsollier et al., which did not have strong off-target candidates based on BLAST search 
and predictions of binding energies (23).  Our studies of FM10 PMO also evaluate its cell 
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toxicity and in vivo effect on DUX4, which are essential in pursuing therapeutic 
development. Future studies will be needed to evaluate the efficacy of repeated and 
systemic administration of PMOs in knocking down DUX4 target gene expression, and 
although the pathophysiology of FSHD remains incompletely understood, we anticipate 
that one or more of these DUX4 target genes is responsible for FSHD muscle weakness 
and could serve as a direct therapeutic target. Our findings, therefore, provide 
comprehensive evidence that antisense PMO technology is a potential therapeutic option 
for FSHD.   





Materials and Methods  
Statistics. Statistical methods for each experiment are described in the main text and 
Supplementary Methods. P-values ≤ 0.05 were considered significant, except for the 
RNA-seq analyses in which p-value < 10-4 was considered significant. 
 
Study approvals.  This study was approved by The Johns Hopkins School of Medicine 
Institutional Review Board.  Written informed consent was received from participants 
prior to inclusion in the study. All animal procedures were carried out in accordance with 
an approved IACUC protocol from Johns Hopkins University School of Medicine. 
 
Human subjects, genotyping, and biopsy.  This study was approved by the Johns 
Hopkins School of Medicine Institutional Review Board. Subjects with FSHD and their 
first degree unaffected relatives were recruited and screened for biomaterial 
contributions. FSHD status was determined by pulsed field electrophoresis and southern 
blotting of leukocyte DNA by Dr. Steven A. Moore and the University of Iowa 
Diagnostic Laboratories, and included identification of the EcoRI/BlnI 4q35 D4Z4 repeat 
length with a p13E11 probe, and 4qA/4qB allele typing of HindIII fragments (100-103).  
Subjects with a positive FSHD diagnosis were categorized with an A, B or C designation, 
and unaffected control subjects with a confirmed negative genotype were categorized 
with a U, V, or W designation. Open muscle biopsy was performed on biceps from living 
donors and deltoid muscle was harvested from autopsy (66). Clinical data for subjects 
33A, 33U, 41A, 58A, 61A and 61B are presented in Supplemental Table S5; data for 
remaining subjects were published previously (25). 
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Morpholinos. Phosphorodiamidate morpholino oligonucleotides (PMOs) were 
synthesized by Gene Tools, LLC with a 5’ primary amine modification to facilitate 
conjugation with a cell penetrating peptide (CPP). Sequences of PMOs are shown in 
Supplemental Table S2. 
 
Cell Culture & in vitro morpholino treatment. Primary muscle cells from FSHD 
subjects 03A, 13B, 14A, 15A, 15B, 16A, 17A, 18A, 21A, 33A, 41A and first-degree, 
unaffected relatives 03U, 13U, 14W, 16U, 21U, 33U were cultured as previously 
described (104). To assess PMO activity, cells were cultured until >95% confluent, rinsed 
briefly with PBS (Cellgro), and then differentiated in Opti-MEM (Invitrogen) 
supplemented with 10 uM DUX4-targeting PMO or standard control PMO (Gene Tools, 
LLC). The standard control PMO designed by Gene Tools, LLC targets a human beta-
globin intron mutation that causes beta-thalassemia, and this target is restricted to beta-
thalessemic hematopoietic cells (www.gene-tools.com). Cells were treated with PMOs 
for four days without a medium change, and then harvested for RT-qPCR analysis or 
immunocytochemistry. To identify ED50 of FM10, cells were cultured as above and 
treated with 0-15 uM standard control or FM10 PMO for four days and assayed for RT-
qPCR analysis. Toxicity was assessed with 17A primary muscle cells treated with 0-500 
uM standard control or FM10 morpholinos conjugated to CPP Peptide B (105) in 
triplicate, using the Celltiter-Glo® Luminescent Viability Assay (Promega) according to 
manufacturer’s instructions. Fluorescence was measured using a Tecan Safire II plate 




Antibodies and immunostaining. Myotube cultures treated with DUX4-targeting PMOs 
or standard control PMOs were fixed with 4% formaldehyde, pH 7.4 and immunostained 
with C-terminal specific mouse-anti-DUX4 clone P4H2 (kindly provided by Drs. Stephen 
Tapscott and Linda Geng) as previously described (25). Secondary detection was 
performed using the ABC Elite kit (Vector Labs) and DAB staining. DUX4-positive 
nuclei were counted using DIC microscopy, and total number of nuclei was estimated by 
counting 10 random fields and multiplying by a factor accounting for area screened.  
Muscle cryosections (10 μm) were fixed in ice-cold methanol, blocked with anti-mouse 
IgG (MKB-2213, Vector Laboratories) for 2 hours, incubated in the primary antibodies 
for 1 hour [anti-human spectrin (NCL-SPEC1, Leica, 1:50) and anti-human lamin A/C 
(Ab40567, AbCam, 1:200)], followed by 45 minute incubation with secondary antibodies 
[AlexaFluor 488 goat anti-mouse IgG1, AlexaFluor 594 goat anti-mouse IgG2b 
(Invitrogen, 1:500)] at room temperature. All nuclei were labeled with DAPI in mounting 
medium (P36930, Invitrogen).   
 
RNA isolation, cDNA synthesis and RT-qPCR analyses. RNA was isolated from cells 
or xenografts as previously described (4, 5). cDNA was synthesized using Oligo (dT)16 
and Superscript III reverse transcriptase (Invitrogen).  Primers were synthesized by 
Integrated DNA Technologies. Primer sequences are listed in Supplemental Table S4. 
Cell RT-qPCR reactions were set up in triplicate using iQ SYBR Green Supermix (Bio-
Rad) and amplified on a CFX96 Touch Real-time PCR Detection System (Bio-Rad). 
Results were analyzed using CFX Manager Software, and visualized graphically using 
Microsoft Excel and Graphpad Prism 6. Expression was normalized to RPL13A. From 
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the xenografts, DUX4-fl expression was determined using 100 ng of poly(A)+ cDNA by 
a qRT–PCR as described previously (106). qPCR reactions were performed using 
Taqman Master Mix (BioRad) with specific Taqman assays for ZSCAN4 
(Hs00537549_m1, Life Tech), MBD3L5 (Hs04190573_mH, Life Tech), GUSB 
(Hs99999908_m1, Life Tech) and PPIA (Hs99999904_m1, Life Tech) and run on a CFX 
PCR machine (BioRad). Reactions were set up in duplicate. Statistical tests were 
PPIA and GUSB. The samples where 
DUX4 was not detected were given a Ct of 45 (total cycle number). The control PMO-
treated biopsy group included two 58A, one 61A and one 61B xenograft, and the FM10-
PMO biopsy group included three 58A, one 61A and two 61B xenografts. To address 
between-donor rather than within-donor variance in response to FM10, multiple 
xenografts from the same donor in each treatment were averaged at the ΔCt level, then 
these average levels were used in the paired t-tests of control PMO vs. FM10. Autopsy 
xenografts (n=10 Ctrl and n=6 FM10) were from a single donor,  and were analyzed with 
a two tailed t-test, assuming unequal variance.  
 
RNA sequencing and analysis. High throughput TruSeq stranded mRNA sequencing 
(RNA-seq, 50- or 51-bp paired end) was performed by Expression Analysis. To identify 
differences between FSHD and unaffected muscle cells, sequencing was performed on 4-
day differentiated myotube cells from FSHD subjects 03A, 13B, 14A, 16A, 21A, 33A 
and their first-degree, unaffected relatives 03U, 13U, 14W, 16U, 21U, and 33U 
(respectively). To identify effects of FM10 PMO treatment (both DUX4-dependent and 
off-target effects), 4-day myotubes from FSHD subjects 15A and 17A, and first degree, 
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unaffected relatives, 15V and 17U (respectively), treated with FM10, standard-control 
morpholino, or Opti-MEM medium alone were sequenced. Samples from 17A and 17U 
were treated and sequenced in duplicate, which allows estimation of within-subject 
variance in response to treatment, but the statistical tests reported here depend on 
between-subject variance in response to treatments, and use just the first replicate so that 
all subjects are treated uniformly. (Data from both replicates is shown in Supplemental 
Fig. S3.4). FASTQ files of raw RNA-seq reads were mapped to Ensembl human GRCh37 
reference genome and transcript annotations (version 75) from Illumina iGenomes using 
Tophat2 (2.1.0) (107) and Bowtie2 (2.2.6) (108) with options -r 70 --mate-std-dev 40 for 
the FSHD vs. unaffected data and -r 60 --mate-std-dev 40 for the PMO data (which was 
done later and had a bit shorter average insert length). Counts of reads mapping 
unambiguously to ~63,000 annotated genes were computed using htseq-count (HTSeq-
0.6.1p1, strand-specific mode) (109), and imported into R for tests of differential 
expression using the package edgeR (3.12) (110). Total per-sample counts of these reads 
ranged from 74 - 113 million for the FSHD vs. unaffected data, and from 63 - 72 million 
for the PMO data. Normalization factors for each sample were computed in edgeR with 
the TMM method, and used as offsets when modeling the data with negative binomial 
distributions with the function glmFit. The dispersion parameters were computed with the 
estimateGLMTagwiseDisp function, shrinking the per-gene estimates toward trended 
dispersion estimates, with prior degrees of freedom set to 5.  Likelihood-ratio tests for 
differential expression were performed with the function glmLRT. The model formula for 
the FSHD vs. unaffected comparison was ~ 0 + diseaseGroup + family, and the model 
formula for the PMO comparisons was ~ 0 + diseaseGroup:treatment + subject.  Here the 
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diseaseGroup factor has levels FSHD and unaffected, the treatment factor has levels 
FM10, control, and Opti-MEM, and the family factor and subject factor account for the 
pairings between first-degree relatives and between multiple treatments of subjects, 
respectively.  To make the coefficients identifiable, the sum of the coefficients for family 
was constrained to be zero in the first model, as were the sums of the coefficients for 
FSHD and unaffected subjects in the second model. The three treatments were modeled 
jointly to allow for shared estimates of dispersion parameters. Results for Opti-MEM 
were generally similar to the standard control PMO (e.g. Supplemental Fig. S3.4).  All 
subjects in the FSHD vs. unaffected study were female except for 14A and 14W, which 
were male; thus an additive effect for sex can be absorbed into the family factor, so is not 
used. All subjects in the PMO study were male, except from 15V; as there is just one 
female sample we did not attempt to adjust for sex, but do note that the gene with the 
most significant change for FM10 in unaffected samples was XIST, which is expressed 
from inactivated X-chromosomes; this may be due to the negative-binomial model being 
a particularly poor fit for this gene, whose read count was >10,000-fold higher for the 
female unaffected subject than for the male unaffected subject, as the direction of change 
with FM10 was not consistent in the two subjects. In Fig. 3.2, Supplemental Table S3.1 
and Supplemental Fig. S3.4, a prior count of 1 was used in computing the log2(counts per 
million) and log2(fold-changes), to avoid infinite values; this does not affect the p-values. 
The ~25,000 genes with zero counts in all samples (separately for the FSHD vs. 





Xenograft procedure and local delivery of PMO-ASO. The Institutional Animal Care 
and Use Committee at the Johns Hopkins University School of Medicine approved all 
procedures performed in this study. NOD-Rag1null null immunodeficient mice (NRG) 
(Stock 007799, The Jackson Laboratory) were used. The xenografting procedure was 
performed with biceps muscle biopsies from FSHD subjects 58A, 61A, and 61B, as 
previously described (95). Human skeletal muscle xenografts which had fully regenerated 
in host NRG mice for 4~6 months were used in this study. For delivery of PMO-ASO, 
xenografts were first injected with 12 µl of 0.4U/μl bovine hyaluronidase (Sigma 
Aldrich). Two hours later, xenografts were injected with 20 µg (1 µg /µl) of PMO-
Standard ASO or PMO-FM10 ASO. Immediately following injection, the ASO was 
electroporated using the parameters of 50 V/cm, 10 pulses at 1 Hz, and 20 ms duration 
per pulse. Mice were euthanized 2 weeks after electroporation and human xenograft 




Figure 3.1. DUX4 and DUX4 target gene knockdown in FSHD myotubes in vitro. (A) 
Schematic demonstrating DUX4-fl transcript and relative targets of PMOs; PAS, 
polyadenylation signal. (B) FSHD biomarker expression analysis of 4-day FSHD 
myotube cultures treated with standard control or DUX4-targeting morpholinos. 
Significant decreases in CCNA1, MBD3L2, TRIM43, and ZSCAN4 biomarker expression 
were observed in myotube cultures treated with 10 uM FM10 (*p-value<0.05, Student’s 
t-test performed on DCts normalized to RPL13A); an intermediate effect was observed in 
FM9-treated cultures. Data are presented as the mean fold change ± SEM relative to 
standard control morpholino. (C) DUX4 protein expression analysis of 4-day FSHD 
myotube cultures treated with standard control or DUX4-targeting morpholinos. DUX4 
protein was detected by immunostaining with C-terminal DUX4-specific P4H2 antibody. 
The greatest decrease in DUX4-positive nuclei was observed in myotube cultures treated 







Figure 3.2. RNA-seq analysis of FSHD vs. unaffected myotube cultures and FM10 
vs. control PMO-treated myotube cultures. These volcano plots show log2(fold-
change) versus -log10(p-value) for tests of differential expression of approx. 37,000 genes 
detected by RNA-seq, for three comparisons: (A) myotube cultures from FSHD subjects 
vs. unaffected first-degree relatives (n=6 pairs); (B) FM10 vs. control (CTRL) PMO-
treated myotube cultures from FSHD subjects (n=2); and (C) FM10 vs. control (CTRL) 
PMO-treated myotube cultures from unaffected subjects (n=2). The two subjects in (B) 
are first-degree relatives of the two subjects in (C), and are unrelated to the 12 subjects in 
(A). To aid in comparisons between plots, the color-coding of points in all plots is 
determined by direction and significance of changes in (A): genes whose expression is 
higher in FSHD than control myotubes are colored red if p-value < 10-4 and pink 
otherwise; genes whose expression is lower in FSHD than control myotubes are colored 
blue if p-value < 10-4 and light blue otherwise. In all plots, black squares are overlaid on 
the DUX4 targets from Table S1 of Yao et al. (10). P-values are from likelihood-ratio 
tests for negative binomial regression (R package edgeR), and prior counts of 1 were 







Figure 3.3. In vivo validation of FM10 knockdown of DUX4-fl and DUX4 target 
genes in a human FSHD xenograft model.  (A) Schematic of the in vivo study design. 
FSHD patient muscle was transplanted into the tibialis anterior space of NRG mice. 
Xenografts fully regenerated in the mouse leg for more than four months, were treated 
with Control- or FM10- PMO via electroporation, and harvested after two weeks. (B) 
Histology of a four-month FSHD xenograft. Immunohistochemistry of the human-
specific muscle membrane protein spectrin and nuclear envelope protein lamin A/C 
confirmed that the xenograft was well regenerated. Human spectrin (red), human lamin 
A/C (green), DAPI (blue). Scale bar: 200 μm. (C) Expression analysis of DUX4-fl and 
(D) of DUX4 target genes MBD3L5 and ZSCAN4 in xenografts from biopsy and autopsy 
donor groups treated with Control- and FM10-PMOs. Significant decreases were 
observed for all three genes with FM10 treatment (**P < 0.01; *P < 0.05, all tests two-
tailed). Statistical tests were performed on DCts, normalized to PPIA and GUSB. The 
biopsy group consisted of xenografts from three donors (n=4 Ctrl; n=6 FM10); to address 
between-donor rather than within-donor variance in response to FM10, DCts for 
xenografts from each donor were averaged, and a paired t-test performed on the per-
donor averages. All xenografts in the autopsy group were from a single donor (n=10 Ctrl; 
n=6 FM10), and an unequal variance t-test was used for this data. Expression levels for 
each xenograft are shown as fold-changes relative to the per-donor mean DCt for the Ctrl 











Supplemental Table S 3.1.  125 genes differentially expressed (with p-value < 
10-4) in myotubes of FSHD patients versus unaffected first degree relatives, 
sorted by p-value. Column names beginning LCPM, LFC, P and FDR indicate 
log2(counts per million), log2(fold-change), p-value, and false-discovery rate, 
respectively, and the suffix of the column name indicates the comparison: FvsU for 
FSHD vs. control myotubes; FM10.F for FM10 vs. control PMO in FSHD myotubes; 
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and FM10.U for FM10 vs. control PMO is unaffected myotubes. The column Yao.S1 is 
Y if the gene appears in Supplemental Table S1, “Robust DUX4 regulated genes in 
human myoblasts transduced with human DUX4”, of Yao et al (86), N otherwise. 
 
gene_id gene_name LCPM.FvsU LFC.FvsU P.FvsU FDR.FvsU LFC.FM10.F P.FM10.F FDR.FM10.F LFC.FM10.U P.FM10.U FDR.FM10.U Yao.S1 
ENSG00000229571 PRAMEF26 -1.16 5.5 9.80E-35 3.90E-30 -1.67 3.60E-08 8.90E-05 0 1.00E+00 1 Y 
ENSG00000180532 ZSCAN4 1.94 4.79 2.40E-30 4.80E-26 -1.65 6.70E-07 1.00E-03 0.43 4.10E-01 1 Y 
ENSG00000268799 RP11-321E2.13 -1.43 4.97 1.90E-29 2.10E-25 -1.47 1.70E-04 1.10E-01 0.57 2.50E-01 1 N 
ENSG00000204455 TRIM51BP -2.07 4.76 2.10E-29 2.10E-25 -1.55 3.60E-05 3.40E-02 -0.01 9.80E-01 1 Y 
ENSG00000128253 RFPL2 -0.41 5.4 1.40E-28 1.10E-24 -1.43 8.40E-04 3.30E-01 0.74 3.20E-01 1 Y 
ENSG00000176979 TRIM60 -2.28 4.43 3.50E-28 2.30E-24 -1.92 2.80E-08 7.90E-05 0 1.00E+00 1 N 
ENSG00000251258 RFPL4B 0.83 5.72 7.70E-28 4.40E-24 -1.55 1.40E-08 4.20E-05 0.08 8.90E-01 1 Y 
ENSG00000128250 RFPL1 -2.25 4.42 1.50E-27 7.30E-24 -1.65 2.70E-04 1.50E-01 -0.59 2.40E-01 1 Y 
ENSG00000116721 PRAMEF1 0.75 5.7 2.00E-27 8.60E-24 -1.97 2.40E-10 2.20E-06 -0.05 9.40E-01 1 Y 
ENSG00000267908 ZSCAN5D -0.96 3.76 3.80E-27 1.50E-23 -1.51 1.90E-07 3.60E-04 1.01 1.00E-01 1 N 
ENSG00000232423 PRAMEF6 -2.21 4.5 6.80E-27 2.40E-23 -1.15 2.10E-03 5.50E-01 0 1.00E+00 1 Y 
ENSG00000204449 TRIM49C -2.57 4.4 3.40E-26 1.10E-22 -1.02 1.30E-03 4.10E-01 -0.6 2.30E-01 1 Y 
ENSG00000249620 RP11-321E2.10 -1.1 4.67 8.10E-26 2.50E-22 -1.28 4.70E-05 4.30E-02 -0.01 1.00E+00 1 Y 
ENSG00000225581 TRIM53AP -1.75 4.27 8.80E-26 2.50E-22 -1.52 4.40E-03 7.90E-01 0 1.00E+00 1 Y 
ENSG00000168930 TRIM49 -1.56 4.48 1.20E-25 3.10E-22 -0.7 3.60E-02 1.00E+00 0.58 2.40E-01 1 Y 
ENSG00000179412 HNRNPCP5 -0.89 4.85 1.30E-25 3.10E-22 -1.36 5.90E-07 9.20E-04 1 9.80E-02 1 Y 
ENSG00000204495 PRAMEF13 -2.41 4.21 1.30E-24 3.10E-21 -1.49 2.10E-06 2.80E-03 0.97 1.10E-01 1 Y 
ENSG00000182315 MBD3L3 -1.81 4.57 1.90E-24 4.30E-21 -1.24 1.20E-04 9.20E-02 0.57 2.50E-01 1 Y 
ENSG00000223638 RFPL4A -1.41 4.45 6.70E-24 1.40E-20 -1.01 5.70E-03 8.60E-01 -0.76 3.00E-01 1 Y 
ENSG00000243073 PRAMEF4 -2.12 3.93 7.10E-24 1.40E-20 -1.48 4.80E-06 6.00E-03 0 1.00E+00 1 Y 
ENSG00000239810 WI2-3308P17.2 -1.97 4.16 9.70E-24 1.80E-20 -1.45 1.40E-04 9.90E-02 0 1.00E+00 1 Y 
ENSG00000179172 HNRNPCL1 -0.25 5.44 1.00E-23 1.90E-20 -1.76 5.70E-10 3.50E-06 1.54 2.30E-02 1 Y 
ENSG00000124900 TRIM51 -1.73 4.42 1.40E-23 2.40E-20 -1.27 7.90E-04 3.30E-01 0 1.00E+00 1 Y 
ENSG00000254104 RP11-63E5.1 -1.71 3.82 5.80E-23 9.60E-20 -1.06 1.20E-03 3.90E-01 0.01 1.00E+00 1 Y 
ENSG00000150244 TRIM48 -2.96 4.22 6.40E-23 1.00E-19 -0.58 2.20E-01 1.00E+00 -1.78 1.20E-02 1 Y 
ENSG00000120952 PRAMEF2 0.67 5.37 1.50E-22 2.20E-19 -1.75 4.40E-11 5.40E-07 1.57 2.10E-02 1 Y 
ENSG00000214325 AC025287.1 -2.35 3.92 1.90E-22 2.80E-19 -0.95 1.70E-02 1.00E+00 -0.02 9.70E-01 1 Y 
ENSG00000213921 LEUTX 1.41 5.83 2.00E-22 2.90E-19 -1.62 1.50E-07 3.00E-04 2.04 4.60E-03 1 Y 
ENSG00000249910 TRIM51CP -2.52 3.78 5.10E-21 7.00E-18 -1.14 4.10E-02 1.00E+00 1.25 5.90E-02 1 Y 
ENSG00000144188 TRIM43CP -2.92 4.03 9.90E-21 1.30E-17 -0.99 2.40E-03 5.90E-01 -0.02 9.70E-01 1 Y 
ENSG00000144015 TRIM43 0.31 5.47 1.20E-20 1.60E-17 -1.85 4.10E-09 1.60E-05 2.76 1.20E-04 0.78 Y 
ENSG00000254764 TRIM53CP -1.95 3.88 2.30E-20 2.80E-17 -1.38 2.80E-04 1.50E-01 0 1.00E+00 1 Y 
ENSG00000204480 PRAMEF19 -3.59 3.38 3.10E-20 3.70E-17 -0.64 5.90E-03 8.70E-01 0 1.00E+00 1 Y 
ENSG00000233834 AC005083.1 -2.59 3.62 1.10E-19 1.30E-16 -1.89 1.10E-03 3.70E-01 0.56 2.60E-01 1 Y 
ENSG00000256980 KHDC1L -2.29 3.3 1.70E-19 1.90E-16 -1.19 6.40E-04 3.00E-01 -0.01 9.80E-01 1 Y 
ENSG00000235268 KDM4E 0 5.45 1.30E-18 1.40E-15 -1.52 2.20E-05 2.30E-02 -0.01 9.90E-01 1 Y 
ENSG00000251163 CTD-2325A15.2 -2.91 3.88 3.80E-18 4.00E-15 -1.44 4.70E-04 2.50E-01 -0.57 2.40E-01 1 Y 
ENSG00000219061 TRIM51FP -2.67 3.45 5.00E-18 5.20E-15 -0.86 5.70E-02 1.00E+00 0.97 1.10E-01 1 Y 
ENSG00000133101 CCNA1 3.94 4.2 6.90E-18 7.00E-15 -1.73 5.00E-07 8.20E-04 0.96 1.20E-02 1 Y 
ENSG00000166013 TRIM53BP -2.74 3.44 7.60E-18 7.50E-15 -0.95 1.40E-02 1.00E+00 -0.59 2.40E-01 1 Y 
ENSG00000250782 RP11-432M8.13 -2.68 3.68 8.50E-18 8.30E-15 -0.96 9.80E-03 9.50E-01 -0.6 2.30E-01 1 Y 
ENSG00000187545 PRAMEF10 -3.12 3.78 9.20E-18 8.60E-15 -1.32 7.60E-04 3.20E-01 0 1.00E+00 1 Y 
ENSG00000269466 RP11-432M8.17 -0.47 4.57 1.30E-17 1.20E-14 -1.67 5.00E-05 4.50E-02 1.27 5.30E-02 1 N 
ENSG00000144010 TRIM43B 0.22 5.27 1.50E-17 1.30E-14 -1.61 3.00E-10 2.20E-06 0.3 6.30E-01 1 Y 
ENSG00000251360 KHDC1P1 -1.03 4.43 1.50E-17 1.30E-14 -1.42 1.30E-03 4.10E-01 -0.01 1.00E+00 1 Y 
ENSG00000204513 PRAMEF11 -1.08 5.01 1.80E-17 1.50E-14 -1.53 1.10E-07 2.30E-04 0.97 1.90E-01 1 Y 
ENSG00000258873 DUXA -0.68 4.35 2.20E-17 1.90E-14 -1.07 7.10E-03 9.20E-01 0.56 2.50E-01 1 N 
ENSG00000237194 SNAI1P1 -2.61 3.63 2.50E-17 2.10E-14 -0.7 6.10E-02 1.00E+00 -1.01 9.40E-02 1 Y 
ENSG00000249357 RP11-432M8.8 -2.07 3.42 3.70E-17 3.00E-14 -0.72 6.70E-02 1.00E+00 0.97 1.90E-01 1 Y 
ENSG00000204481 PRAMEF14 -3.31 3.72 9.90E-17 7.90E-14 -1.43 2.80E-09 1.30E-05 0 1.00E+00 1 Y 
ENSG00000182053 TRIM49B -1.48 4.38 1.10E-16 8.80E-14 -1.19 1.30E-04 9.20E-02 -0.03 9.70E-01 1 Y 
ENSG00000250386 RP11-432M8.11 -1.25 3.7 2.10E-16 1.60E-13 -1.25 7.70E-05 6.20E-02 1.75 1.20E-02 1 Y 
ENSG00000230268 SSU72P8 -3.3 3.61 2.80E-16 2.10E-13 -0.36 4.80E-01 1.00E+00 0 1.00E+00 1 Y 
ENSG00000257951 RP11-554D14.4 2.13 5.73 1.00E-15 7.40E-13 -1.25 3.20E-03 6.90E-01 1.95 4.40E-03 1 Y 
ENSG00000229292 RFPL4AL1 -2.4 3.69 6.40E-15 4.60E-12 -0.71 6.30E-02 1.00E+00 -1.33 4.20E-02 1 Y 
ENSG00000249156 RP11-432M8.9 -1.85 3.17 8.00E-15 5.70E-12 -0.75 8.70E-02 1.00E+00 0.34 6.30E-01 1 Y 
ENSG00000255855 RP11-735A19.2 -2.94 3.48 2.50E-14 1.70E-11 -1.28 9.70E-04 3.60E-01 -0.01 9.80E-01 1 Y 
ENSG00000220948 TRIM51GP -3.21 3.3 3.80E-14 2.60E-11 -1.81 2.50E-04 1.40E-01 0 1.00E+00 1 Y 
ENSG00000178928 TPRX1 -1.44 2.38 1.60E-13 1.10E-10 -0.62 6.10E-02 1.00E+00 -0.88 1.70E-01 1 Y 
ENSG00000116726 PRAMEF12 1.21 5.5 5.90E-13 3.90E-10 -1.69 1.10E-09 5.90E-06 -0.54 4.50E-01 1 Y 
ENSG00000218725 RP11-174C7.2 -3.25 3.08 6.20E-13 4.00E-10 -0.65 6.00E-03 8.70E-01 0 1.00E+00 1 Y 
ENSG00000239275 RP4-675G8.2 -3.72 3.22 8.20E-13 5.30E-10 -1.29 7.50E-06 8.50E-03 0 1.00E+00 1 Y 
ENSG00000186232 SSU72P3 -3.77 3.21 1.00E-12 6.50E-10 0.16 7.50E-01 1.00E+00 0 1.00E+00 1 Y 
ENSG00000157765 SLC34A2 3.38 5.7 1.10E-12 6.70E-10 -1.99 1.20E-20 4.60E-16 1.25 2.10E-03 1 Y 
ENSG00000236217 C1DP2 -2.74 3.19 4.20E-12 2.60E-09 -1.78 5.00E-06 6.00E-03 0 1.00E+00 1 Y 
ENSG00000165929 TC2N -1.41 3.48 4.70E-12 2.80E-09 -1.06 1.80E-03 5.00E-01 -0.61 4.00E-01 1 Y 
ENSG00000230522 MBD3L2 0 5 7.80E-12 4.60E-09 -0.96 1.90E-03 5.00E-01 1.29 4.80E-02 1 Y 
ENSG00000189253 TRIM64B -3.64 3.09 1.90E-11 1.10E-08 -1.08 8.20E-03 9.30E-01 0 1.00E+00 1 Y 
ENSG00000224199 WI2-2994D6.1 -3.6 3 2.90E-11 1.70E-08 -1.37 1.70E-02 1.00E+00 0 1.00E+00 1 Y 
ENSG00000237247 MBD3L5 -3.8 3.02 3.50E-11 2.00E-08 -0.61 2.80E-01 1.00E+00 0 1.00E+00 1 Y 
 
 70 
ENSG00000229542 SSU72P7 -3.77 2.98 3.80E-11 2.10E-08 -0.7 2.50E-01 1.00E+00 0.57 2.60E-01 1 Y 
ENSG00000223417 TRIM49D1 -3.74 2.96 8.20E-11 4.50E-08 -0.87 2.90E-03 6.50E-01 -0.6 2.30E-01 1 Y 
ENSG00000237706 TRIM51EP -3.55 2.97 9.40E-11 5.10E-08 -1.79 4.30E-09 1.60E-05 0 1.00E+00 1 Y 
ENSG00000255194 SSU72P2 -3.76 2.83 4.00E-10 2.10E-07 -0.55 2.50E-01 1.00E+00 0 1.00E+00 1 Y 
ENSG00000249666 RP11-432M8.12 -3.35 2.94 6.70E-10 3.60E-07 -0.72 2.00E-01 1.00E+00 0 1.00E+00 1 Y 
ENSG00000188460 ACTBP11 -3.57 2.65 1.30E-09 6.70E-07 -1.02 6.10E-02 1.00E+00 0 1.00E+00 1 Y 
ENSG00000214534 ZNF705E -1.32 2.68 1.40E-09 7.10E-07 -1.19 7.30E-06 8.50E-03 0.28 5.50E-01 1 Y 
ENSG00000188536 HBA2 -4.3 2.42 1.90E-09 9.70E-07 -1.9 5.30E-05 4.60E-02 0.57 2.50E-01 1 Y 
ENSG00000197123 ZNF679 -4.04 2.49 2.40E-09 1.20E-06 -0.08 8.80E-01 1.00E+00 0 1.00E+00 1 Y 
ENSG00000214295 FOXO1B -3.38 2.74 2.60E-09 1.30E-06 -0.51 4.30E-01 1.00E+00 0 1.00E+00 1 N 
ENSG00000251076 RP11-526F3.1 -3.59 2.63 2.90E-09 1.40E-06 -0.92 2.80E-02 1.00E+00 1.29 4.90E-02 1 Y 
ENSG00000204479 PRAMEF17 -4.06 2.67 3.70E-09 1.80E-06 -0.9 6.90E-02 1.00E+00 0 1.00E+00 1 Y 
ENSG00000229978 RP13-221M14.3 -4.08 2.61 7.90E-09 3.80E-06 -1.03 1.20E-04 9.20E-02 0 1.00E+00 1 Y 
ENSG00000196946 ZNF705A -1.12 4.1 9.70E-09 4.60E-06 -1.55 1.80E-05 2.00E-02 1.12 1.20E-01 1 Y 
ENSG00000166007 TRIM51HP -4.25 2.53 1.60E-08 7.30E-06 -1.55 2.50E-02 1.00E+00 0 1.00E+00 1 Y 
ENSG00000205622 AF064858.6 -2.58 3.02 2.20E-08 9.90E-06 -1.11 1.40E-02 1.00E+00 -1.8 1.10E-02 1 Y 
ENSG00000251393 RP1-240K6.3 -2.71 1.75 2.30E-08 1.00E-05 -0.02 9.50E-01 1.00E+00 -0.95 2.90E-01 1 N 
ENSG00000204532 ZSCAN5C -3.99 2.5 5.30E-08 2.40E-05 -2.22 1.30E-07 2.70E-04 0 1.00E+00 1 Y 
ENSG00000128276 RFPL3 -4.25 2.21 5.90E-08 2.60E-05 0 1.00E+00 1.00E+00 0 1.00E+00 1 Y 
ENSG00000187569 DPPA3 -3.21 2.48 7.10E-08 3.10E-05 -0.17 6.50E-01 1.00E+00 0 1.00E+00 1 Y 
ENSG00000236941 RP11-366M4.8 -0.98 2.25 9.10E-08 4.00E-05 -1.27 1.90E-06 2.70E-03 -0.54 3.10E-01 1 N 
ENSG00000269118 FAM90A28P -3.67 2.42 9.60E-08 4.20E-05 -0.79 1.60E-01 1.00E+00 0 1.00E+00 1 N 
ENSG00000206172 HBA1 -4.46 2.16 1.30E-07 5.60E-05 -0.68 1.90E-01 1.00E+00 1.8 1.00E-02 1 Y 
ENSG00000188782 CATSPER4 -3.84 2.4 1.40E-07 6.10E-05 0 1.00E+00 1.00E+00 0 1.00E+00 1 N 
ENSG00000204711 C9orf135 -4.18 2.21 4.60E-07 1.90E-04 -0.97 1.60E-01 1.00E+00 -0.59 2.40E-01 1 N 
ENSG00000269067 ZNF728 -3.76 2.14 4.70E-07 1.90E-04 -0.95 1.30E-01 1.00E+00 -0.56 2.50E-01 1 N 
ENSG00000147256 ARHGAP36 -1.88 -2.44 5.10E-07 2.10E-04 -0.18 6.70E-01 1.00E+00 0.14 7.00E-01 1 N 
ENSG00000229361 UBTFL7 -3.71 2.45 5.30E-07 2.20E-04 -0.65 9.80E-03 9.50E-01 0 1.00E+00 1 Y 
ENSG00000227160 RP1-65P5.1 -4.25 2.23 5.60E-07 2.30E-04 -1.07 5.20E-02 1.00E+00 -0.43 5.60E-01 1 N 
ENSG00000087510 TFAP2C -3.19 2.07 9.40E-07 3.70E-04 -0.69 2.40E-01 1.00E+00 1.17 1.30E-01 1 N 
ENSG00000189348 FAM90A27P -4.17 2.14 9.70E-07 3.80E-04 -1 5.20E-03 8.40E-01 0 1.00E+00 1 Y 
ENSG00000204503 PRAMEF3 -4.49 2.15 1.10E-06 4.40E-04 -0.2 4.40E-01 1.00E+00 0.01 1.00E+00 1 Y 
ENSG00000171872 KLF17 -0.74 2.37 3.10E-06 1.20E-03 -0.45 1.90E-01 1.00E+00 -0.27 6.10E-01 1 Y 
ENSG00000214003 ATP5F1P3 -4.62 2.01 3.20E-06 1.20E-03 -0.28 5.40E-01 1.00E+00 0 1.00E+00 1 N 
ENSG00000196589 CTB-25J19.1 -4.59 2.02 3.80E-06 1.40E-03 0.08 8.90E-01 1.00E+00 0 1.00E+00 1 Y 
ENSG00000261723 CTD-2196E14.3 -3.15 2.58 4.30E-06 1.60E-03 -1.05 1.60E-02 1.00E+00 -1.3 4.60E-02 1 N 
ENSG00000197584 KCNMB2 -1.91 -1.99 4.60E-06 1.70E-03 -0.14 7.30E-01 1.00E+00 0.73 3.10E-02 1 N 
ENSG00000272382 CTD-2035E11.4 -1.42 2.3 5.70E-06 2.10E-03 -1.12 4.00E-03 7.60E-01 0.5 4.50E-01 1 N 
ENSG00000228709 AP001065.15 -2.2 1.74 6.40E-06 2.30E-03 -1.02 1.00E-02 9.60E-01 0.52 4.90E-01 1 N 
ENSG00000206077 ZDHHC11B -3.93 1.92 8.30E-06 3.00E-03 -1.11 3.10E-01 1.00E+00 -1.32 7.60E-02 1 N 
ENSG00000156453 PCDH1 1.46 1.32 9.50E-06 3.40E-03 0.05 8.60E-01 1.00E+00 0.21 3.80E-01 1 N 
ENSG00000235890 TSPEAR-AS1 -3.41 1.52 1.30E-05 4.80E-03 -0.97 2.90E-01 1.00E+00 -0.77 3.40E-01 1 N 
ENSG00000223912 EEF1A1P36 -4.79 1.82 1.50E-05 5.40E-03 -2.32 5.00E-04 2.60E-01 0 1.00E+00 1 Y 
ENSG00000204478 PRAMEF20 -4.3 2 1.80E-05 6.20E-03 -0.81 1.30E-01 1.00E+00 0 1.00E+00 1 Y 
ENSG00000257842 NOVA1-AS1 -3.87 2.34 1.90E-05 6.70E-03 -1.16 1.60E-02 1.00E+00 -0.58 2.40E-01 1 N 
ENSG00000108602 ALDH3A1 -0.11 -1.39 2.60E-05 8.90E-03 -0.29 3.30E-01 1.00E+00 0.65 2.40E-02 1 N 
ENSG00000130303 BST2 -1.23 1.33 2.70E-05 9.20E-03 -0.96 2.10E-02 1.00E+00 0.7 1.30E-01 1 N 
ENSG00000255065 RP11-680E19.2 -4.17 1.86 3.60E-05 1.20E-02 -1.57 1.70E-03 4.80E-01 -0.01 9.80E-01 1 Y 
ENSG00000255268 RP11-707M1.9 -4.72 1.71 4.90E-05 1.60E-02 -0.79 3.10E-01 1.00E+00 0 1.00E+00 1 N 
ENSG00000154639 CXADR -1.45 1.71 4.90E-05 1.60E-02 -1.09 1.30E-04 9.20E-02 0.32 6.10E-01 1 N 
ENSG00000255452 RP11-107P7.1 -4.59 1.82 5.00E-05 1.60E-02 -0.49 4.50E-01 1.00E+00 0 1.00E+00 1 N 
ENSG00000267654 RP11-973H7.4 -4.22 1.67 5.30E-05 1.70E-02 -0.13 8.30E-01 1.00E+00 1.28 5.10E-02 1 N 
ENSG00000104267 CA2 -1 1.93 5.50E-05 1.80E-02 -0.32 4.30E-01 1.00E+00 -0.17 7.30E-01 1 Y 
ENSG00000259383 RP11-403B2.6 -4.17 -1.73 6.50E-05 2.10E-02 0 1.00E+00 1.00E+00 0 1.00E+00 1 N 




Supplemental Table S 3.2. Morpholino sequences directed at the DUX4 
transcript. 
 










Supplemental Table S 3.3.  46 genes differentially expressed (with p-value < 
10-4) in FM10 vs. control PMO-treated FSHD myotubes, sorted by p-value. 
Column names beginning LCPM, LFC, P and FDR indicate log2(counts per million), 
log2(fold-change), p-value, and false-discovery rate, respectively, and the suffix of 
the column name indicates the comparison: FvsU for FSHD vs. control myotubes; 
FM10.F for FM10 vs. control PMO in FSHD myotubes; and FM10.U for FM10 vs. 
control PMO is unaffected myotubes. The column Yao.S1 is Y if the gene appears in 
Supplemental Table S1, “Robust DUX4 regulated genes in human myoblasts 
transduced with human DUX4”, of Yao et al (86), N otherwise. 
 
gene_id gene_name LCPM.FvsU LFC.FvsU P.FvsU FDR.FvsU LFC.FM10.F P.FM10.F FDR.FM10.F LFC.FM10.U P.FM10.U FDR.FM10.U Yao.S1 
ENSG00000157765 SLC34A2 3.38 5.7 1.10E-12 6.70E-10 -1.99 1.20E-20 4.60E-16 1.25 2.10E-03 1 Y 
ENSG00000164879 CA3 0.12 1.53 5.50E-03 6.10E-01 -1.64 3.30E-13 6.20E-09 -0.26 3.90E-01 1 N 
ENSG00000120952 PRAMEF2 0.67 5.37 1.50E-22 2.20E-19 -1.75 4.40E-11 5.40E-07 1.57 2.10E-02 1 Y 
ENSG00000116721 PRAMEF1 0.75 5.7 2.00E-27 8.60E-24 -1.97 2.40E-10 2.20E-06 -0.05 9.40E-01 1 Y 
ENSG00000144010 TRIM43B 0.22 5.27 1.50E-17 1.30E-14 -1.61 3.00E-10 2.20E-06 0.3 6.30E-01 1 Y 
ENSG00000179172 HNRNPCL1 -0.25 5.44 1.00E-23 1.90E-20 -1.76 5.70E-10 3.50E-06 1.54 2.30E-02 1 Y 
ENSG00000116726 PRAMEF12 1.21 5.5 5.90E-13 3.90E-10 -1.69 1.10E-09 5.90E-06 -0.54 4.50E-01 1 Y 
ENSG00000204481 PRAMEF14 -3.31 3.72 9.90E-17 7.90E-14 -1.43 2.80E-09 1.30E-05 0 1.00E+00 1 Y 
ENSG00000144015 TRIM43 0.31 5.47 1.20E-20 1.60E-17 -1.85 4.10E-09 1.60E-05 2.76 1.20E-04 0.78 Y 
ENSG00000237706 TRIM51EP -3.55 2.97 9.40E-11 5.10E-08 -1.79 4.30E-09 1.60E-05 0 1.00E+00 1 Y 
ENSG00000229616 RP11-369J21.11 -4.69 1.42 8.80E-02 1.00E+00 -2.36 1.30E-08 4.20E-05 0 1.00E+00 1 N 
ENSG00000251258 RFPL4B 0.83 5.72 7.70E-28 4.40E-24 -1.55 1.40E-08 4.20E-05 0.08 8.90E-01 1 Y 
ENSG00000176979 TRIM60 -2.28 4.43 3.50E-28 2.30E-24 -1.92 2.80E-08 7.90E-05 0 1.00E+00 1 N 
ENSG00000156510 HKDC1 0.13 1.41 1.40E-04 4.30E-02 -1.88 3.00E-08 8.00E-05 -0.25 5.00E-01 1 N 
ENSG00000229571 PRAMEF26 -1.16 5.5 9.80E-35 3.90E-30 -1.67 3.60E-08 8.90E-05 0 1.00E+00 1 Y 
ENSG00000205718 MBD3L4 -5.38 0.31 1.80E-01 1.00E+00 -4.74 6.40E-08 1.50E-04 0 1.00E+00 1 Y 
ENSG00000204513 PRAMEF11 -1.08 5.01 1.80E-17 1.50E-14 -1.53 1.10E-07 2.30E-04 0.97 1.90E-01 1 Y 
ENSG00000204532 ZSCAN5C -3.99 2.5 5.30E-08 2.40E-05 -2.22 1.30E-07 2.70E-04 0 1.00E+00 1 Y 
ENSG00000213921 LEUTX 1.41 5.83 2.00E-22 2.90E-19 -1.62 1.50E-07 3.00E-04 2.04 4.60E-03 1 Y 
ENSG00000267908 ZSCAN5D -0.96 3.76 3.80E-27 1.50E-23 -1.51 1.90E-07 3.60E-04 1.01 1.00E-01 1 N 
ENSG00000239776 AC079949.1 6 -0.06 7.30E-01 1.00E+00 -1.93 3.00E-07 5.40E-04 0.68 6.10E-02 1 N 
ENSG00000136943 CTSV -0.66 -0.02 9.60E-01 1.00E+00 -1.59 3.20E-07 5.40E-04 -0.11 7.40E-01 1 N 
ENSG00000133101 CCNA1 3.94 4.2 6.90E-18 7.00E-15 -1.73 5.00E-07 8.20E-04 0.96 1.20E-02 1 Y 
ENSG00000179412 HNRNPCP5 -0.89 4.85 1.30E-25 3.10E-22 -1.36 5.90E-07 9.20E-04 1 9.80E-02 1 Y 
ENSG00000180532 ZSCAN4 1.94 4.79 2.40E-30 4.80E-26 -1.65 6.70E-07 1.00E-03 0.43 4.10E-01 1 Y 
ENSG00000236941 RP11-366M4.8 -0.98 2.25 9.10E-08 4.00E-05 -1.27 1.90E-06 2.70E-03 -0.54 3.10E-01 1 N 
ENSG00000158246 FAM46B 0.22 0.59 6.40E-02 1.00E+00 -1.45 1.90E-06 2.70E-03 0.13 6.90E-01 1 N 
ENSG00000181652 ATG9B -2.68 0.06 8.40E-01 1.00E+00 -2.21 2.10E-06 2.80E-03 -1.67 5.70E-03 1 N 
ENSG00000204495 PRAMEF13 -2.41 4.21 1.30E-24 3.10E-21 -1.49 2.10E-06 2.80E-03 0.97 1.10E-01 1 Y 
ENSG00000243073 PRAMEF4 -2.12 3.93 7.10E-24 1.40E-20 -1.48 4.80E-06 6.00E-03 0 1.00E+00 1 Y 
ENSG00000236217 C1DP2 -2.74 3.19 4.20E-12 2.60E-09 -1.78 5.00E-06 6.00E-03 0 1.00E+00 1 Y 
ENSG00000214534 ZNF705E -1.32 2.68 1.40E-09 7.10E-07 -1.19 7.30E-06 8.50E-03 0.28 5.50E-01 1 Y 
ENSG00000239275 RP4-675G8.2 -3.72 3.22 8.20E-13 5.30E-10 -1.29 7.50E-06 8.50E-03 0 1.00E+00 1 Y 
ENSG00000196946 ZNF705A -1.12 4.1 9.70E-09 4.60E-06 -1.55 1.80E-05 2.00E-02 1.12 1.20E-01 1 Y 
ENSG00000235605 RP5-827C21.1 -1.67 -0.15 5.60E-01 1.00E+00 -2.64 1.80E-05 2.00E-02 1.75 9.40E-04 1 N 
ENSG00000125966 MMP24 -1.06 0.05 8.90E-01 1.00E+00 -1.53 2.20E-05 2.30E-02 -0.13 7.00E-01 1 N 
ENSG00000235268 KDM4E 0 5.45 1.30E-18 1.40E-15 -1.52 2.20E-05 2.30E-02 -0.01 9.90E-01 1 Y 
ENSG00000260808 CTD-2007L18.5 -4.72 -0.17 7.40E-01 1.00E+00 -2.58 3.40E-05 3.40E-02 0.57 2.50E-01 1 N 
ENSG00000204455 TRIM51BP -2.07 4.76 2.10E-29 2.10E-25 -1.55 3.60E-05 3.40E-02 -0.01 9.80E-01 1 Y 
ENSG00000249620 RP11-321E2.10 -1.1 4.67 8.10E-26 2.50E-22 -1.28 4.70E-05 4.30E-02 -0.01 1.00E+00 1 Y 
ENSG00000269466 RP11-432M8.17 -0.47 4.57 1.30E-17 1.20E-14 -1.67 5.00E-05 4.50E-02 1.27 5.30E-02 1 N 
ENSG00000265150 RN7SL2 6.62 -0.31 1.80E-01 1.00E+00 0.91 5.30E-05 4.60E-02 0.18 4.00E-01 1 N 
ENSG00000188536 HBA2 -4.3 2.42 1.90E-09 9.70E-07 -1.9 5.30E-05 4.60E-02 0.57 2.50E-01 1 Y 
ENSG00000183150 GPR19 -3.25 0.22 5.50E-01 1.00E+00 -2.12 6.50E-05 5.50E-02 0.59 2.70E-01 1 N 
ENSG00000197409 HIST1H3D -4.04 -0.06 9.30E-01 1.00E+00 -2.41 6.80E-05 5.60E-02 -1.76 1.20E-02 1 N 
ENSG00000250386 RP11-432M8.11 -1.25 3.7 2.10E-16 1.60E-13 -1.25 7.70E-05 6.20E-02 1.75 1.20E-02 1 Y 
ENSG00000170684 ZNF296 -1.92 1.28 1.30E-04 3.90E-02 -1.26 8.30E-05 6.60E-02 -0.91 1.60E-01 1 Y 
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Supplemental Table S 3.4. RT Primer Sequences 
Gene Forward Primer Sequence Reverse Primer Sequence 
RPL13A* AACCTCCTCCTTTTCCAAGC  
 
GCAGTACCTGTTTAGCCACGA 
CCNA1* TGAAGCAGATCCATTCTTGAAA  
 
ACCCTGTAAATGCAGCAAGG 
MBD3L2* GCGTTCACCTCTTTTCCAAG  
 
GCCATGTGGATTTCTCGTTT 
TRIM43* ACCCATCACTGGACTGGTGT  
 
CACATCCTCAAAGAGCCTGA 






DUX4-fl AGCTTTAGGACGCGGGGTTGGGAC GCAGGTCTGCWGGTACCTGG 















33A Proband F 49 28 kb (4qB), 
20 kb (4qA) 
5/5 
33U Sister of 
33A 
F 45 77 kb (4qd), 47 kb 
(4qB), 27 kb (4qB)e 
5/5 
41A Proband F 34 14 kb (4qA), 
102 kb (4qA) 
4+/4+ 
58A Proband M 50 27kb(4qA), 
157kb(4qA) 
4+/4+ 
61A Proband M 61 17kb(4qA), 
77kb(4qA), 
82 kb (4qB)e 
5/5 
61B Sister of 
proband 
F 60 17kb(4qA), 
72kb(4qA), 
82 kb (4qB)e 
5/5 
* Clinical characteristics of subjects not listed here were published previously (25). 
a
Donors are designated by cohort (family) number (01, 03, etc.) followed by A, B or 
C for the FSHD subjects or U, V or W for the unaffected first-degree relative(s).  
b
FSHD1 was confirmed by presence of a shortened 4qA type D4Z4 repeat array 
identified by an EcoRI/BlnI restriction fragment of <35 kb (Supplementary 
Material). Shortened repeat arrays are shown in bold. 
c
Muscle strength (right/left) is presented using a modified MRC scale where 5 is full 
strength and side of biopsy is underlined.  
d4qA/4qB status was not determined. 
e
Subjects with three BlnI resistant chromosomes (designated as chromosome 4q-
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type array) showed only one BlnI-sensitive chromosome (designated as 
chromosome 10-type array) resulting in an apparent chromosome 4q:10q array 





Supplemental Fig. S 3.1. RT-qPCR analysis of primary FSHD myotube cultures 
treated with 10 uM standard control (n=4), FM4 (n=2), FM8 (n=3), FM9 (n=4) 
or FM10 (n=4) morpholinos.  Data are plotted as ΔCt values, normalized to 
RPL13A expression, and mean ±SEM is noted. Significant differences in FSHD 
biomarker expression levels between control and FM10 morpholino-treated 







Supplemental Fig. S 3.2. FM10 and standard control MOs were conjugated to 
Peptide B and tested for cytotoxicity. FM10-PPMO treatment was not associated 
with significant in vitro cytotoxicity over 48 hour treatment with 0 to 500 uM PPMO.  

















FM10 (n=3)  Control (n=3)
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Supplemental Fig. S 3.3. ED50 assay of FM10. MBD3L2 and ZSCAN4 biomarker 
expression was assayed by RT-qPCR in primary myotubes from FSHD subjects 
17A, 18A, and 41A treated with 0 to 15 uM FM10 or standard control (Ctrl) 
MO. Data are plotted as Ct normalized to RPL13A with mean ± SEM noted (top) 
and average fold change relative to untreated (bottom) ± SEM. Maximal effects 
were observed at 12.5 uM, and ED50 ≤ 2.5 uM. 
 
  



































































































































Supplemental Fig. S 3.4. RNA-seq counts for five DUX4 target genes and MYH1, 
a marker of myogenic cell differentiation. Vertical axes show log2(counts per 
million reads), with 1 prior count added before scaling; this gives genes with no 
counts scores around -6, and small changes in counts have larger effects on 
log2(CPM) when counts are low.  Gene names are shown at the top of each plot, and 
each gene has two associated plots: (1) the FSHD vs. unaffected myotube study, with 
six FSHD (red circles) and six unaffected subjects (black circles), and dashed lines 
connecting first-degree relatives; (2) the PMO study, with four subjects (two FSHD 
in red, two unaffected in blue), each in three conditions, Opti-MEM medium alone 
(Opti, empty circles), standard control PMO (Ctrl, saturated solid circles), and FM10 
PMO (FM10, pale solid circles). Dashed lines connect first-degree relatives in Opti-
Mem, and solid lines connect treatments of the same sample (bold line connects 
Opti-MEM and control PMO, pale line connects control PMO and FM10). Treatments 
for 17A and 17U are done in duplicate, with triangles replacing circles for the 
second replicate. Note that because the two RNA-seq experiments were done at 
different times there may be batch effects that remain even after normalization, so 
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In this work, we described the successful establishment a novel human skeletal 
muscle xenograft model for FSHD by transplanting FSHD affected donor muscle into the 
anterior tibial compartment of immunodeficient NRG mice hind limbs. The grafted 
muscles from fresh biopsy donors and autopsy donors were regenerated by graft 
myocytes, re-vascularized by graft and host blood vessels, and re-innervated by host 
motor neurons. Currently, the loss of transcriptional repression of DUX4 in the D4Z4 
macrosatellite repeats at chromosome 4q35 is believed to be the causative genetic defect 
of FSHD. In our human muscle xenografts, DUX4 expression as well as the FSHD 
biomarker profile mirrored those of the donor muscle tissue, making this model a feasible 
and valid preclinical tool to predict the response to novel therapeutics for FSHD (Chapter 
2). We report a proof-of-concept study to investigate the therapeutic potential of DUX4 
targeting antisense oligonucleotide therapy for FSHD in our human muscle xenograft 
model and show promising knockdown of DUX4 expression and significant reduction in 
two FSHD biomarkers (Chapter 3).  
   
Future Directions  
This xenograft model provides an opportunity to study the effects of age and 
disease on the innate regenerative and growth capacity of human skeletal muscle in vivo. 
The fact that the regenerated muscle was integrated into the mouse host’s vascular and 
nervous system but retained the clear separation from mouse muscle guaranteed the 
recreation of the human muscle microenvironment and cell-cell interactions in a 
physiological condition.  
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The recapitulation of disease biomarker profile in the FSHD xenografts compared 
to the original patient biopsy showed great promise to apply this xenograft model in 
disease pathogenesis investigation and pre-clinical therapeutic development of more 
skeletal muscle myopathies. Preliminary experiments have been done to create xenograft 
from patient biopsies from Duchenne muscular dystrophy (DMD) and inclusion body 
myositis (IBM) to investigate the disease pathogenesis, and it could be adapted to many 
more.     
Our xenograft model also provides a platform to study human muscle 
regeneration in vivo. The transplanted muscle tissue is damaged from the biopsy process, 
but retained the intact 3-D structure of muscle tissue, and we have shown that the satellite 
cell activation and new muscle fiber formation happen within the extracellular matrix 
structure of the original muscle fibers. Further exploration of the specific progression of 
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